



Here for a Healthier World

www.enfermedical.ie

Contents

1.0	INTRODUCTION	
2.0	ENFER MEDICAL SUPPORTING OLOLHD GENERAL PRACTITIONERS	
3.0	STANDARD REQUIREMENTS FROM GENERAL PRACTITIONERS	5
3.1 "CR	PROVISION OF EMERGENCY CONTACT DETAILS FOR REPORTING OF ITICAL RESULTS" OUTSIDE NORMAL PRACTICE HOURS	5
3.2	CRITERIA REQUIRED FOR LABELLING PATIENT SPECIMENS	7
3.3	CRITERIA REQUIRED FOR MANUAL PATIENT REQUEST FORMS	7
3.4	CRITERIA REQUIRED FOR SENDING URGENT SPECIMENS	9
3.5 SPE	PROTOCOLS FOR 24-HOUR STABILITY AND SAME-DAY URGENT CIMEN PROCESSING	. 10
4.0	SPECIMEN TRANSPORT	. 12
5.0	PRE-ANALYTICAL GUIDANCE	. 13
6.0	CRITICAL RESULTS REPORTING GUIDE	. 14
7.0	COMMUNICATION	. 16
8.0	CLINICAL ADVISORY SERVICES	. 17
9.0	CHRONIC DISEASE MANAGEMENT	. 18
10.0	VITAMIN D TESTING AND GUIDELINES	. 19
11.0	USER FEEDBACK	. 19
12.0	DATA PROTECTION	. 20
APPE	NDIX 1:	. 22
	of HSE Approved Laboratory tests routinely available to OLOLHD	. 22
	NDIX 2: Specimen Stability/Collection Guidance, TATs and ence ranges for Approved Services for OLOLHD	. 24
	NDIX 2.1: Sickle Cell Screen/Thalassaemia Demographics and rence Range	. 67
APPE	NDIX 3: Specimen receipt anomalies (Specimen receipt anomaly col and codes)	

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 2 of 78

FOREWORD

Enfer Medical is committed to being the most accessible and efficient clinical diagnostic laboratory service in Ireland. Our goal is always to provide a high level of service to our colleagues in the health services, on behalf of their patients. We are clinically led and patient focused. We strive to continually improve our operational expertise, responding to the needs of our users and providing innovative testing solutions.

The Enfer Medical team works to the highest possible standards in all aspects of the company's business. We subscribe to ISO 15189:2022 international standard of accreditation and are accredited by the Irish National Accreditation Board (INAB) for medical testing. We are strongly committed to service development and the continuous professional development of our team to maintain excellence in all our undertakings.

The purpose of this manual is to act as a reference guide for the provision of a quality service to General Practitioners (GPs) and for their adult patients operating and residing, primarily, within their respective catchment areas. Specimens are processed from adults aged 16 years or older.

GPs requiring access to services at Enfer Medical should reside within the designated Hospital HSE Hub areas for Our Lady of Lourdes Hospital Drogheda and can only request the service as agreed with Our Lady of Lourdes Hospital Drogheda.

GPs requiring access to services that are outside the scope of general practice are required to contact Our Lady of Lourdes Hospital, Drogheda, as this is not included in the testing service at Enfer Medical.

Included in the manual are details about the scope of service, requirements from GPs, range of tests available, expected turnaround times, our location, hours of operation, contact details for key personnel, availability of clinical advice, and other relevant information to allow users to easily access our services.

Rosemary Curran Medical Director

Document No: EMQM007 Date of Issue: 18/04/2025 Issued by: M. Buggy Approved by: P. Simmons

Revision: 002

Page: 3 of 78

1.0 INTRODUCTION

Enfer Medical provides a clinical diagnostic laboratory service in the specialities of clinical chemistry, haematology, microbiology, immunology, virology, and genomics. Our service is available to all public and private hospital laboratories, general practitioners, and clinicians from private services throughout Ireland. The laboratory is consultant-led, patient-centred, and quality-focused. A clinical advisory service is available for healthcare professionals and includes advice on the interpretation of individual patient results and appropriate patient management pathways.

The Enfer Medical team works to the highest possible standards in all aspects of the company's business. We subscribe to both ISO 15189:2022 international standard of accreditation and the highest standards of continuous professional development to maintain excellence in all our undertakings. In December 2021, we were awarded our INAB (Irish National Accreditation Board) certificate, registration number 395MT, and we are accredited to the ISO 15189:2022 standard as a medical testing laboratory. We are strongly committed to service development and to the provision of innovative testing solutions for our users.

Our list of accredited tests is detailed in our INAB Schedule of accreditation, and this, alongside our accreditation certificate, are both available on our website (https://www.enfermedical.ie/enfermedical-accreditation/). The schedule provides details on the test or assay used, specimen types, equipment or technique, and the relevant procedure number in use.

For the purpose of this User Manual, we have included in Appendix 1 to this document, a list of tests available to Our Lady of Lourdes Hospital Drogheda GPs.

Clients will be immediately notified of any changes to testing that may impact ongoing testing. We also provide updates to changes on the schedule of accreditation through our website. Enfer Medical is committed to the sustained innovation of our services through continuous quality improvement, which may include formal academic research and the evaluation of novel approaches aimed at improving the health of patients and the wellbeing of the wider population.

Contact Us:

Enfer Medical, Unit T, M7 Business Park, Newhall, Naas, Co. Kildare, Ireland, W91FD74

Tel: + 353 45 819 000

Email:

Client Services: clientqueries@enfermedical.ie
Clinical Queries: gpclinicalqueries@healthmail.ie

Website: www.enfermedical.ie



Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 4 of 78

2.0 ENFER MEDICAL SUPPORTING OLOLHD GENERAL PRACTITIONERS

Enfer Medical is committed to providing a quality service to General Practitioners (GPs) and for their adult patients operating and residing, primarily, within the OLOLHD catchment areas. Specimens are processed from adults aged 16 years or older. The defined timelines for the delivery and receipt of patient GP specimens collected by General Practitioner services for testing in Enfer Medical are Monday to Friday from 8 am to 6 pm.

The current test repertoire available to General Practitioners is determined by the OLOLHD laboratory consultants, based on best practice guidelines, including the requirements of national programmes. Medical scientists may assess the suitability of any laboratory tests ordered and reject requests based on laboratory procedures, technical/scientific competency, and patient history.

The aim of this manual is to:

- 1. Provide guidance to General Practitioners on the procedures and standards required to ensure a safe and effective laboratory service.
- 2. Define the laboratory investigations routinely available to GPs.
- 3. Outline the standard requirements from GPs in the receipt of the laboratory services.

The laboratory testing services available to General Practitioners are listed in the Appendix 1 to this User Manual, where information on individual tests is available. Laboratory tests not listed in Appendix 1 will be reviewed and assessed based on clinical information provided.

The laboratory at Enfer Medical processes and tests specimens until from 08:00 AM to 10:00 PM daily. This ensures a prompt turnaround for all test results.

3.0 STANDARD REQUIREMENTS FROM GENERAL PRACTITIONERS

Enfer Medical operates a normal service between 8am and 10pm. All GP practitioners are responsible for developing a system whereby test results returned from Enfer Medical are examined and appropriate action is taken in a timely manner.

Enfer Medical requires a register of General Practitioners (GPs) and all health care professionals and services who send specimens to the laboratory, including details of the appropriate contact number for transmission of critical results.

3.1 PROVISION OF EMERGENCY CONTACT DETAILS FOR REPORTING OF "CRITICAL RESULTS" OUTSIDE NORMAL PRACTICE HOURS

It is recognised that occasionally, unexpected critically abnormal results are found on analysis, such that laboratory staff become aware of a potential emergency before the treating General Practitioners. In these circumstances, laboratory staff must follow procedures to contact the requesting GP to relay the result.

Enfer Medical supports the communication of critical results to GP practices and Our Lady of Lourdes Hospital, Drogheda (OLOLHD) and follows these general steps:

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons

1. Routine Hours Reporting:

Critical results are reported directly to GP practices during their routine operating hours (Monday to Friday, 9:00 am to 6:00 pm) using the contact details provided by the practice.

2. Out-of-Hours Reporting:

All General Practitioners requiring laboratory medicine services <u>MUST</u> provide contact details for the reporting of "critical" results outside normal practice hours (*Reference: HSE Communication of Critical Results for Patients in the Community National Laboratory Handbook*). THIS IS A REQUIREMENT FOR ACCESS TO HSE APPROVED LABORATORY SERVICES PROVIDED BY ENFER MEDICAL.

GP practices are responsible for establishing an agreed pathway for out-of-hours critical result communication. This may include direct contact to be provided to Enfer Medical via a designated mobile number or through an agreement with a proxy agency like North East Doc On Call (NEDOC). Where a proxy agency e.g. NEDOC is used by a GP Service, arrangements must be made between the relevant parties to ensure that markedly abnormal results can be telephoned directly to the agency, without complication and that follow-up action can occur. This is a critical clinical risk management issue for all parties concerned. It is important to note that the recording of the patient's phone number on the request form will assist communication between parties.

IMPORTANT: Enfer Medical will follow the agreed protocol for out-of-hours reporting. However, if all avenues are exhausted, including attempts to contact the GP out-of-hours contact and/or any designated proxy agency, Enfer Medical will have no choice but to record all attempts at reporting the critical result and report the critical result on the next working day.

Additionally, where "Out of Hours Contact Information" is not provided by GPs referring patient specimens for testing at Enfer Medical and where Enfer Medical cannot fulfil its' obligation to report a critical result in accordance with statutory requirements, then referring GPs acknowledge and accept that Enfer Medical, will have no choice but to record all attempts at reporting the critical result and report the critical result on the next working day. The referring GP shall be responsible for the receiving of these critical results and any delays arising.

Emergencies

In rare life-threatening emergencies, such as a new diagnosis of acute leukaemia or Thrombotic Thrombocytopenia Purpura (TTP), Enfer Medical will escalate this directly to the OLOLHD laboratory if the GP out-of-hours contact and proxy services are unreachable. This is subject to the relevant clinical information being provided in the patient request form received for this patient.

3. Documentation:

Enfer Medical will document all critical result communication, including the date, time, individuals involved, results conveyed, verification of communication accuracy, and any challenges encountered during notification.

By adhering to agreed protocols and documenting all actions taken, Enfer Medical ensures a robust and reliable process for managing critical results in collaboration with GP practices and OLOLHD.

IMPORTANT: While Enfer Medical supports the communication pathways for critical results, the responsibilities and agreements with GP practices and proxy agencies lie with the respective parties.

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 6 of 78 Enfer Medical remains a facilitating partner to ensure smooth and effective communication of critical results.

3.2 CRITERIA REQUIRED FOR LABELLING PATIENT SPECIMENS

The use of printed labels produced by the GP practice management system, tailored to the specimen container size, is the preferred labelling method as it enhances the accuracy and legibility of information.

We have outlined below, both mandatory and desirable criteria for the labelling of patient specimens.

MANDATORY:

All specimens, including the specimen container, must be labelled with the following minimum dataset:

- **Patient's Full Name:** Surname and forename must be clearly identified. Please note that addressograph/patient labels must clearly differentiate between the patient's surname and forename.
- Patient's Date of Birth
- Date of Collection: The date when the specimen was collected.
- **Time of Collection:** The time of collection is a mandatory requirement to determine specimen integrity and of importance also for self-collected specimens such as stool specimens.

DESIRABLE:

- **Gender of Patient:** Particularly important where investigations have gender-related reference ranges (e.g., hormone testing).
- Specimen Type or Site: For non-blood specimens (e.g., MSU, Ear Swab).

Important: Kindly note that incomplete labelling requirements or where minimum criteria is not met, this may lead to specimen rejection. This could result in the need for a repeat specimen, potentially causing inconvenience to patients and delaying results. Enfer Medical has developed a schedule of Specimen Receipt Anomalies (SRAs), describing the scenarios in which testing analysis may be affected and/specimens may be rejected. This Schedule of SRAs also outlines scenarios in which testing proceeds but where test comments are included with results.

We appreciate your attention to ensuring all forms are fully completed to avoid any disruptions.

3.3 CRITERIA REQUIRED FOR MANUAL PATIENT REQUEST FORMS

We respectfully request that he Request Form accompanying the specimen/specimen be legibly written. The legibility of the manual request form is crucial to ensure accurate patient details. Use of block capitals or a clearly typed form is recommended to reduce errors in patient identification, test selection, or location.

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons

Revision: 002 Date of Issue: 18/04/2025 Page: 7 of 78 **MANDATORY:** The Request Form must include the following minimum dataset:

- Patient's Full Name: Forename and surname
- Patient's Date of Birth
- Patient's Address: This is a mandatory field required for Healthlink result transfer
- Date of Collection: The date when the specimen was collected
- Time of Collection: Required in specific cases, such as stool specimen testing
- **Requesting Doctor's Name and MCRN:** Used as the destination for the report (GP practice stamp and sticker are very welcome).
- Specimen Type/Site: Mandatory for all non-blood specimens (e.g., Ear Swab, MSU)
- Laboratory Test Required: Please ensure that all laboratory test names are used exactly as they appear in Appendix 1. This consistency is crucial for our specimen reception team to accurately match incoming specimens with the correct tests, reducing delays and minimizing errors during intake. In situations where there is uncertainty regarding the requested test name then testing will be put on hold pending clarification with the requesting GP.

STRONGLY RECOMMENDED:

- **Gender:** Especially relevant where Male or Female are significant
- Patient's Clinical Details and Relevant History: Including drug, anticoagulant, or antibiotic therapy, to aid in the interpretation of results
- Patient Preparation Conditions: Such as fasting


Certain investigations may require additional information on the specimen or request form and we encourage GPs to provide all relevant clinical information where available.

Important: Kindly note that incomplete patient request forms may lead to specimen rejection. This could result in the need for a repeat specimen, potentially causing inconvenience to patients and delaying results. We appreciate your attention to ensuring all forms are fully completed to avoid any disruptions.


Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons

Revision: 002 Date of Issue: 18/04/2025 Page: 8 of 78

OLOLHD Microbiology Request Form:



OLOLHD Blood Science Request Form:



IMPORTANT:

The use of the GP Practice stamp and printed sticker are best practice when completing manual patient request forms.

All writing on the request form must be clearly legible (BLOCK CAPITALS preferred) so that the information provided is legible, thus ensuring proper identification of the patient and all tests requests. Writing should be in ballpoint pen (not marker) to ensure the information is copied through to each sheet of the request form.

3.4 CRITERIA REQUIRED FOR SENDING URGENT SPECIMENS

is important to follow specific steps to ensure quick identification and efficient handling by the laboratory. The following guidelines will help prioritise your samples and ensure that all necessary information is clearly communicated:

• Clearly mark both the specimen and the patient request form as **URGENT**.

Document No: EMQM007 Revision: 002
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 9 of 78

- Confirm all information on the label and request form is complete and legible, verifying test names are accurate as per Appendix 1.
- PROVIDE THE CLINICAL REASON FOR THE URGENT REQUEST IN ADDITION TO OUT OF HOURS CONTACT DETAILS FOR THE REFERRING CLINICIAN ON THE REQUEST FORM. IN THE ABSENCE OF EITHER, SPECIMENS WILL BE PROCESSED AS ROUTINE REQUESTS.
- Place the specimen and patient request form into the provided RED URGENT SPECIMEN BAG for easy identification.
- **NOTIFY** the laboratory of the urgent status upon collection to help expedite processing. Email or call Enfer Medical on 353 (0)45 819000 or <a href="mailto:specification-specificati





3.5 PROTOCOLS FOR 24-HOUR STABILITY AND SAME-DAY URGENT SPECIMEN PROCESSING

IMPORTANT: PLEASE NOTE THAT THE FOLLOWING TESTS HAVE A 24-HOUR STABILITY AND FOR GPS WHO DO NOT HAVE A DAILY COLLECTION OF SPECIMENS FROM HSE PRIMARY CARE LOGISTICS, THEN WE KINDLY ADVISE THAT THE FOLLOWING TESTS ARE ONLY CARRIED OUT ON DAYS THAT SPECIMENS ARE COLLECTED FOR DELIVERY TO THE LABORATORY.

- Urine Chlamydia/Gonorrhoea (please note that the 24hr stability applies where a general urine pot is used, the use of Aptima urine collection pots extends stability to 30 days).
- ESR specimens should be tested within 24 hours of collection, however, specimens over 24hrs and under 48hrs can be tested but will be reported with a test comment.
- Blood Film please note that where an FBC result reflexes to a Blood Film, specimens must be <= 24 hours to proceed to Blood Film analysis.
- Pro-BNP Specimens must be spun within 24 hours and tested within 6 days of collection and stored at 2-8°C.
- Potassium Specimens must be tested within 1 day of collection if spun and stored at 2-8°C. Specimens must be tested within 4 hours if unspun.
- TPO Antibodies Specimens must be spun within 8 hours and tested within 3 days of collection and stored at 2-8°C. Remove serum from the clot if testing will be delayed for more than 8 hours.

Document No: EMQM007 Revision: 002
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 10 of 78

- Anti Thyroglobulin Antibody Specimens must be spun within 8 hours and tested within 3 days of collection and stored at 2-8°C. Remove serum from the clot if testing will be delayed for more than 8 hours.
- Cortisol Specimens must be spun within 8 hours and tested within 7 days of collection and stored at 2-8°C. Remove serum from the clot if testing will be delayed for more than 8 hours.

COAGULATION TEST PROTOCOLS FOR SAME-DAY PROCESSING

At Enfer Medical, we recognise the importance of timely warfarin dosing in patient care. To support GPs in delivering effective treatment, coagulation requests, including Prothrombin Time (PT) and International Normalised Ratio (INR), will be processed on the same day they are received. To facilitate same, it is essential that the process for requesting urgent specimen analysis as outlined above is adhered to when submitting Coagulation specimens.

By following these guidelines, you will help ensure that coagulation tests are prioritised and processed promptly, allowing for timely patient management and critical decision-making, such as adjusting warfarin doses within the required 24-hour window.

POTASSIUM TESTING - SAMPLE COLLECTION AND PROCESSING CRITERIA

Potassium testing requires careful attention to timing due to its short stability i.e. the sample must be tested within 4 hours of sample collection time, as it is unstable beyond this point. Given the time delay between sample collection times and the delivery of samples to Enfer Medical, Enfer Medical in the majority of cases may not be in position to provide a potassium test. However, if samples are centrifuged within 4 hours of being drawn from the patient, they can be tested at Enfer Medical, provided they have been centrifuged at 3500rpm for 10 minutes. This process helps to extend the testing window, allowing the sample to remain viable for analysis. It is essential to include the centrifuge speed, duration and time of centrifugation on the PRF to meet the necessary testing criteria and ensure accurate results. Additionally, please ensure that the process for requesting urgent specimen analysis as outlined above is adhered to when submitting requests for potassium analysis.

Instructions for Potassium Testing and Sample Handling

Timing and Stability:

- Potassium samples are highly time-sensitive and must be tested within 4 hours of sample collection.
- Samples that are not tested within this 4-hour window will be considered unstable and cannot be processed at Enfer Medical.

Centrifugation Criteria (to extend testing window):

If centrifuging the sample within 4 hours of collection, it can be processed at Enfer Medical, provided the following conditions are met:

- The sample must be centrifuged at 3500rpm for 10 minutes.
- This procedure helps to preserve the stability of the sample, extending the testing window and allowing the potassium test to be performed beyond the initial 4-hour period.

Document No: EMQM007
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 11 of 78

Documentation Requirements:

It is critical to include the following details on the PRF (Patient Request Form) to ensure the sample meets testing criteria:

- Centrifuge Speed (3500rpm)
- Centrifuge Duration (10 minutes)
- Time of Centrifugation (specific time the centrifugation process was completed)

4.0 SPECIMEN TRANSPORT


OLOLHD GPs currently receive dedicated support from the HSE Primary Care logistics team to collect and transport specimens from GP practices to OLOLHD.

To ensure the timely processing and integrity of specimens, Enfer Medical collects specimens twice daily from OLOLHD for delivery to Enfer Medical in Naas at 2:30pm and 4.30/5pm. This systematic approach allows for seamless logistics, minimizing delays and maintaining the integrity of the specimens. The Enfer Medical logistics team and partners are committed to providing a reliable service that meets the needs of OLOLHD GPs and their patients. Specimens are handled with care and transported promptly; we aim to uphold the highest standards of clinical excellence.

In accordance with the ADR 2019 Safety Legislation, there are specific packaging instructions and labelling requirements requiring triple packaging including:

- ✓ Primary leak-proof container tube or vial containing the specimen.
- ✓ Secondary watertight packaging, with absorbent material, intended to protect the primary container i.e. biohazard envelope.
- ✓ Outer rigid container protects the secondary container.
- \checkmark Patient Request forms must be placed between the secondary container and the outer shipping container.

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 12 of 78



5.0 PRE-ANALYTICAL GUIDANCE

Factors affecting test results - Specimen Stability:

Serum specimens which are highly haemolysed, or hyperlipaemic should not be sent to the laboratory. We have provided detailed specimen stability information for each test in Appendix 2.

In the absence of daily specimen pick-up from individual GP practices by the HSE Primary Care logistics team, specimens sent to Enfer Medical may have been taken some time prior to their arrival at the laboratory. This could potentially lead to stability issues, which may affect the accuracy and reliability of the test results.

It is crucial that GPs refer to Appendix 2, "Specimen Collection Guidance for Approved Services for Our Lady of Lourdes Hospital Drogheda," to ensure that specimens remain stable and suitable for testing, particularly for those with stabilities under 24-48 hours.

Proper adherence to these guidelines helps to maintain the quality and integrity of the specimens during transportation and processing.

Criteria for rejection of specimens:

Document No: EMQM007 Revision: 002
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 13 of 78

In rare cases specimens may not be suitable for testing on arrival to the laboratory. In that case the specimen will be rejected at the receipt stage and the service user will be notified immediately and an explanation as to why the specimen could not be processed will be provided. Reasons why specimens are rejected include but are not limited to:

- Specimens received beyond the stability limits and/or not at the correct temperature indicated for each test.
- Incorrect specimen type received.
- Leaking specimens, specimen not received or specimen insufficient for analysis as stated below within specimen requirements.
- Non-compliant specimens or request forms, i.e., those missing specimen date information, missing specimen test request and/or missing specimen site/type information.
- Specimens received without the necessary patient identifiers.
- Problems during transport of specimens where the specimen is compromised.
- Illegibility

The laboratory reports SRAs (Specimen Receipt Anomalies) within 4 hours of identification of an issue to facilitate prompt recall of patients if required. Please review the SRA policy and Appendix 3 within.

6.0 CRITICAL RESULTS REPORTING GUIDE

Please review the following *Enfer Medical Critical Results Guide and Procedure* for specific result details.

Category	Reporting
Category A	Results require communication within 2 hours. This classification indicates potential immediate danger to the patient, or a potential life-threatening illness when urgent intervention is required.
Category B	Results require Communication within 24 hours, and preferably on the same working day.
Category C	Results could have an immediate impact on a patient's management (either treatment or investigation) however action is likely to be taken on the next working day. Communication on the next working day is satisfactory.

Microbiology			
Analyte	Result	Category	
C. difficile*	Toxin Positive	A	

Document No: EMQM007
Issued by: M. Buggy D
Approved by: P. Simmons

Faecal Microbiological Analysis*	V	A	
HBsAg*	Detected	В	
HCV Ab*	Detected	В	
HIV 1 or 2*	Detected - new detection only		В
Surveillance Screen -CPE (rectal/stool)*	Posit	В	
	Any unex		
Swab (Pus / Fluid aspirate)	(unusual patho patient likely to empir	С	
Treponema Pallidum*	Positive spec detection in	В	
	Haemato	logy	
Analyte	Critical Low	Critical High	Category
Analyte Blood Film Morphology	Critical Low		Category A
	Critical Low	Critical High Blasts	
Blood Film Morphology	Critical Low E Significan	Critical High Blasts It schistocytes	A
Blood Film Morphology Haemoglobin	Critical Low E Significan	Critical High Blasts at schistocytes ≥ 20.0 g/dL	A B
Blood Film Morphology Haemoglobin INR Neutrophil Count	Critical Low Significant <7.0 g/dL	Critical High Blasts at schistocytes ≥ 20.0 g/dL	A B A
Blood Film Morphology Haemoglobin INR	Critical Low Significan <7.0 g/dL ≤ 0.5 x 10 ⁹ /L	Critical High Blasts at schistocytes ≥ 20.0 g/dL	A B A A
Blood Film Morphology Haemoglobin INR Neutrophil Count	Critical Low Significan <7.0 g/dL ≤ 0.5 x 10 ⁹ /L ≤ 30 x 10 ⁹ /L	Critical High Blasts at schistocytes ≥ 20.0 g/dL ≥5.0	A B A A
Blood Film Morphology Haemoglobin INR Neutrophil Count Platelet Count	Critical Low Significan <7.0 g/dL ≤ 0.5 x 10 ⁹ /L ≤ 30 x 10 ⁹ /L	Critical High Blasts at schistocytes ≥ 20.0 g/dL ≥5.0 ≥ 600 x 10 ⁹ /L	A B A A B
Blood Film Morphology Haemoglobin INR Neutrophil Count Platelet Count White Blood Cell Count	Critical Low Significan <7.0 g/dL ≤ 0.5 x 10 ⁹ /L ≤ 30 x 10 ⁹ /L	Critical High Blasts at schistocytes ≥ 20.0 g/dL ≥5.0 ≥ 600 x 10 ⁹ /L ≥ 30 x 10 ⁹ /L	A B A A B B B
Blood Film Morphology Haemoglobin INR Neutrophil Count Platelet Count White Blood Cell Count PT*	Critical Low Significan <7.0 g/dL ≤ 0.5 x 10 ⁹ /L ≤ 30 x 10 ⁹ /L	Critical High Blasts at schistocytes ≥ 20.0 g/dL ≥5.0 ≥ 600 x 10°/L ≥ 30 x 10°/L >40 seconds	A B A A B B C

	Biochemistry				
Analyte	Critical Low	Critical High	Category		
Active B12*	<25 pmol/L		В		
Vitamin B12	≤ 100 pg/L		В		
Adiusted Calsium*	≤ 1.7 mmol/L	≥ 3.5 mmol/L	Α		
Adjusted Calcium*		3.0 - 3.5 mmol/L	В		
ALT*		≥ 510 U/L on first occurrence	A		
Amylase		≥ 625 U/L	Α		
AST*		≥ 510 U/L on first occurrence	A		
Carbamazepine*		≥25 mg/L	Α		
CO2*		>35.0 mmol/L	В		
CO2**	<15.0 mmol/L		Α		

Revision: 002 Date of Issue: 18/04/2025 Page: 15 of 78

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons

Cortisol	≤50 nmol/L		A
Creatine Kinase*		≥ 5000	В
Creatinine		≥ 354 µmol/L (on first occurrence)	A
CRP*		≥ 300 mg/L	В
Digoxin*		≥2.5 µg/L	Α
eGFR	≤ 15 mL/min (on first occurrence)		A
FT4		≥ 50 pmol/L	С
Glucose*	≤ 2.5 mmol/L	≥ 25.0 mmol/L	В
Hypogammaglobulinaemia	IgG <3 g/L		С
Lithium*		>1.5 mmol/L	Α
Magnesium*	≤ 0.3 mmol/L		Α
		IgG >15 g/L	
Paraprotein	Any IgE/IgD	IgA > 10g/L	С
		IgM > 10 g/L	
Phenytoin*		≥25 mg/L	Α
Phoenhouse	≤ 0.3 mmol/L		Α
Phosphorus	≤ 0.45 mmol/L		В
Potassium*	≤ 2.3 mmol/L	≥ 6.0 mmol/L	Α
Sodium*	≤ 120 mmol/L on first occurrence	≥ 155 mmol/L on first occurrence	А
Triglycerides		≥ 20 mmol/L	В
Troponin*		≥99 percentile ng/L on first occurrence	A
TSH		>75 mIU/L	В
Urea		≥ 30 mmol/L on first occurrence	A

Source: Communication of Critical Results for Patients in the Community National Laboratory Handbook 2019 (EMED131) and * as per consultant recommendation.

7.0 COMMUNICATION

Client Services Support

- Enfer Medical is committed to providing a seamless and responsive experience for our clients, including General Practitioners.
- The Client Service Team at Enfer Medical plays a central role in this process, triaging queries in real-time to the appropriate personnel. This enables us to address inquiries as efficiently as possible, aligning with our dedication to exceptional client service. We understand the importance of timely and accurate information, and our commitment to real-time query management reflects our ongoing efforts to exceed client expectations.
- A telephone service for healthcare professionals is available from 08:00 to 20:00 each working day. All enquiries to the laboratory shall be dealt with promptly by the client services team with referral to a member of the laboratory, commercial or clinical team where appropriate.

Document No: EMQM007 Revision: 002
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 16 of 78

Tel no. details: +353 (0) 45 819 000

- Additional communication is facilitated through the ENFER MEDICAL website and by direct contact with the laboratory.
- In the event an urgent report is required, the GP must alert the laboratory by telephone/by email at gpclinicalqueries@healthmail.ie and state the nature of the urgency and must ensure it is clearly indicated on the Request Form. Additionally, the out of hours contact details for the referring clinician must be included in the Request Form.
- Phoning the laboratory for results: Please contact the Client Services team at 353 (0) 45 819 000.

Key Laboratory Personnel

Position	Name
Medical Director	Dr Rosemary Curran
Operations Director	Dr Paul Simmons
Consultant Chemical Pathologist	Prof. Carel Le Roux
Consultant Microbiologist	Dr Rosemary Curran
Consultant Haematologist	Dr Saad Ahmed
Quality Manager	Margaret Buggy
Laboratory Manager	Jonny Finnegan
Laboratory Manager (Genomics)	Elaine Kenny
IT Manager	Tom Tobin
Commercial Director	Dolores Barry
Group Health and Safety Manager	Susan Wall
Clinical Advice	Consultants on duty
Client Services Team	Client Service Team Member
Service Feedback	Commercial and QA Managers
GDPR Requests	Data Protection Officer

8.0 CLINICAL ADVISORY SERVICES

Enfer Medical provides a consultant led clinical advisory service to our users. Our Medical Consultants are responsible for the provision of clinical advice. Our Clinical and Medical Scientists with the appropriate training can provide technical advice on the interpretation of laboratory results.

• OLOLHD GPs may contact members of our Clinical Team between the hours of 08:00 to 18:00 Monday to Friday by email at gpclinicalqueries@healthmail.ie OR by contacting our Client

Document No: EMQM007 Revision: 002
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 17 of 78

Services Team who will direct the query without delay to the relevant member of the Clinical Team (see below) or their Deputy.

Enfer Medical Clinical Advisory Team/Consultants

Position	Name
Consultant Chemical Pathologist	Prof. Carel Le Roux
Deputy Consultant Chemical Pathologist	Dr Royce Vincent
Consultant Haematologist	Dr Saad Ahmed
Deputy Consultant Haematologist	Dr Kanthi Perera
Consultant Microbiologist	Dr Rosemary Curran
Deputy Consultant Microbiologist	Dr Billie Caceda
Deputy Consultant Microbiologist	Dr. Ciaran O'Gorman
Clinical Advice	Relevant Consultant or Clinical/Medical Scientist on duty
Client Services Team	Client Service Team Member

- Enfer Medical takes pride in offering a comprehensive and traceable clinical advisory service to Healthcare Professionals, ensuring optimal support when needed for patient result interpretation and management pathways.
- At Enfer Medical, the Client Service Team plays a central role in this process, triaging queries in real-time to the appropriate personnel. This enables us to address enquiries such as urgent clinical queries as efficiently as possible, aligning with our dedication to exceptional client and clinical service. We understand the importance of timely and accurate information, and our commitment to real-time query management reflects our ongoing efforts to exceed client expectations.

9.0 CHRONIC DISEASE MANAGEMENT

We respectfully request that GPs be cognisant of the national referral criteria for the GP direct access to the Chronic Disease Management program. Please ensure that you only refer tests fulfilling the criteria below to the laboratory, to ensure that this service can be continued.

One NTproBNP test will be facilitated for the first GP Structured Chronic Disease Management registration visit for each patient who has a diagnosis of type 2 diabetes, ischemic heart disease or atrial fibrillation. This is in line with the GP Agreement 2019. An allowance may also be made for individuals who have a pre-existing clinical diagnosis of one of the above chronic diseases and who are already registered on the Structured Chronic Disease Management Programme but who still require an NTproBNP test to establish a baseline for their condition;

Document No: EMQM007 Revision: 002
Issued by: M. Buggy
Approved by: P. Simmons
Page: 18 of 78

- Outside of these criteria, an NTproBNP may be ordered in the following circumstances, where the GP feels it's clinically indicated:
 - 1. For investigation of a patient who has one of the above diagnoses and presents with deterioration in symptoms; consistent with heart failure; and
 - 2. As part of the investigative work up of a patient who presents with symptoms consistent with heart failure.

10.0 VITAMIN D TESTING AND GUIDELINES

Please note that Vitamin D testing should be restricted to specific patient groups as outlined in the HSE Laboratory Services Reform Programme Advice Note (2024) - Indications for the measurement of Vitamin D levels.

See Link Below:

National Guidelines for Vitamin D measurement

National Guidelines Advice for Laboratories and Users

- 1. Vitamin D testing should be reserved for specific patient groups; it should not be used as a general screen.
- 2. In general indications for testing for vitamin D should be one of the following:
 - a) metabolic bone disease
 - Osteoporosis or Osteopaenia i.
 - ii. Rickets or Osteomalacia
 - iii. Paget's Disease of Bone
 - iv. Pathological Fracture
 - Unexplained Hypocalcaemia, raised PTH, low or high Phosphate ٧.
 - b) Specific named clinical condition due to or leading to Vitamin D Deficiency
 - i. Malabsorption, CKD, Liver Disease
 - ii. Muscle weakness
 - iii. Chronic inflammation
 - iv. Certain Drug therapies: Glucocorticoids, Anticonvulsants, Antiretrovirals, Antifungals, Anti Oestrogens or Cholestyramine
- 3. Routine repeat resting is not required. For those with low baseline and malabsorption retesting in 6 months may be helpful.
- 4. The Department of Health have issued advice for the general population regarding vitamin D supplementation (see link above).

11.0 USER FEEDBACK

Enfer Medical highly values client feedback as an integral component of our quality management systems. We actively encourage users to share their experiences, suggestions, or concerns through our dedicated feedback channels. This valuable input not only contributes to the enhancement of our services but is also a testament to our dedication to providing the best possible laboratory experience. Clients can access real-time feedback on our website or submit their comments directly.

Document No: EMQM007 Revision: 002 Date of Issue: 18/04/2025 Issued by: M. Buggy Approved by: P. Simmons

Page: 19 of 78

We prioritise the integration of client feedback into our quality management system meetings, where it forms a crucial part of our discussion points. By engaging with and implementing feedback, Enfer Medical ensures that our laboratory services align with the needs and expectations of our clients, fostering a collaborative and responsive approach to quality assurance.

Beyond improvement efforts, this feedback process is a critical component of our complaints handling process. By actively engaging with and addressing client feedback, we ensure a robust and responsive approach to resolving concerns and maintaining the highest standards of service quality.

Where a GP needs to raise a complaint, they should contact one of the below:

Designated Client Service Contact: Mags Treacy (clientqueries@enfermedical.ie)

- Quality Manager: Margaret Buggy (quality@enfermedical.ie)
- Operations Director: Paul Simmons (paulsimmons@enfermedical.ie)
- Client Services section on www.enfermedical.ie

Or alternatively by raising a ticket here using the following link <u>here</u> or by using the link on our website. The information will be treated as confidential and investigated thoroughly. This process will link into the Quality Management System procedure for incident investigation.

Complaints will be acknowledged on receipt. Resolution of complaints will be undertaken within the shortest timeframe achievable. If resolution cannot be achieved within one month, the complainant will be notified.

The findings and corrective actions are documented in an investigation report, and the findings are then shared with the client, from our Enfer Medical Quality Assurance Manager, within one month of the NC being raised. This transparent and proactive communication ensures clients are informed and reassured about the steps taken to address the issue.

12.0 DATA PROTECTION

Policy on protection of personal information:

Enfer Medical is committed to protecting the privacy of personal information of its service users and patients. In the course of their work our staff are required to collect and use certain types of information about people, including 'personal data' as defined by the Data Protection Act 2018. The service user has a responsibility to ensure that this personal data is:

- Obtained fairly.
- Recorded correctly, kept accurate and up to date.
- Used and shared both appropriately and legally.
- Stored securely.
- Not disclosed to unauthorised third parties.
- Disposed of appropriately when no longer required.

All staff working at Enfer Medical are required under the Data Protection Act 2018 to ensure the security and confidentiality of all personal data they process on behalf of service users and patients.

Document No: EMQM007 Revision: 002
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 20 of 78

13.0 REFERRAL POLICY

For the purposes of additional or confirmatory investigations, specimens may be referred to an accredited external laboratory, where possible. Enfer Medical approves referral Laboratories for use, and these are evaluated, selected, and monitored by the clinical and quality teams at Enfer Medical and will be listed on the Approved Referral Laboratory List. The referral laboratory is clearly identified on the final report.

14.0 CHANGE HISTORY

Revision	Amendment details	Revision Date
1	New document	24/10/2024
2	Section 3.4 - updated criteria for urgent samples Section 3.5 - updated criteria for stability and urgent samples Section 11 - findings shared within one month Section 8 Dr Ciaran O'Gorman added Appendices 1 - 3 updates to test list details and SRAs	18/04/2025

Document No: EMQM007
Issued by: M. Buggy
Approved by: P. Simmons

Revision: 002
Date of Issue: 18/04/2025
Page: 21 of 78

APPENDIX 1: List of HSE Approved Laboratory tests routinely available to OLOLHD GPs (V2)

Bioc	hemistry	Haematology	Immunology	Microbiology
Thyroid Function (Free T4/TSH)	Urate	Vitamin B12/Folate (Fasting sample)	Anti-CCP	Culture & Sensitivity
LH & FSH	Amylase	(i asting sample)	Rheumatoid Factor	Fungal Culture
Cortisol (time must be stated)	Magnesium	Infectious Mononucleosis screen	Thyroid microsomal antibodies (TPO)	Mycobacterial investigation
PSA (Supply Clinical details)	Creatinine Kinase	Coagulation screen (PT & INR only)	Tissue Transglutaminase antibody (tTg) / Anti- Gliadin TTG IgA and TTG IgG	Stool investigation: -Routine Stool Investigation: Bacteria/Bacterial Toxins: Salmonella, Campylobacter, Shigella, VTEC -Extended Stool Investigation: Bacteria and Bacterial Toxins C. difficile Toxin A/B gene, Campylobacter spp., Enteroaggregative E.coli (EAEC), Enteroinvasive E.coli (EIEC)/Shigella, Enterotoxigenic E.coli (ETEC), Enteropathogenic E.coli (EPEC), Plesiomonas shigelloides, Salmonella, Shigatoxin producing E.coli (STEC) stx1/stx2, Shiga-toxin producing E.coli (STEC) O157:H7, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia enterocolitica. Viruses Adenovirus 40/41, Astrovirus, Norovirus GI, Norovirus GII, Rotavirus A, Sapovirus (I, II, IV, V)
Oestrodial	Iron studies	INR (Warfarin) –	IgG/A/M Protein Electrophoresis (SPEP)	Ova & Parasites (based on clinical details) (MOCP)

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 22 of 78

Biochemistry		Biochemistry Haematology Immunology		Microbiology		
Progesterone	Digoxin	ESR	Connective Tissue Disease (CTD) Screen Intrinsic Factor Anti-parietal cell screen ANCA – Vasculitis screen only	Chlamydia / Gonorrhoea / MGEN		
Prolactin	Carbenamazapine	Ferritin	Only 3 Allergy tests permitted:	Herpes Simplex Virus		
Sex Hormone Binding Globulin	Phenobarbitone	G6PD	- Animal Disorders	Varicella Zoster Virus (VZV) IgG (Immune status)		
Testosterone	Phenytoin	Sickle cell/ Thalassaemia	(allergy) - House dust mite (allergy)	STI screen (syphilis, HIV, HBsAg)		
Lithium	B-HCG	FBC & WBC Differential	- Peanut Allergy - Mixed Grass pollen	Measles/Mumps/Rubella IgG screen		
CA 125	Theophylline	- Note for patients with known platelet	(allergy) (This assay includes	Viral Hepatitis B & C screen (HBsAg + anti-HCV)		
CA 15.3	Valproate	clumping, the platelet count	Sweet Vernal Grass,	Hepatitis B Infection status (HBsAg, anti-HBc)		
CA 19.9	C Reactive Protein (CRP)	can be reported on a	Bermuda Grass and	Hepatitis A IgG (HAV IgG)		
Alpha Feto-protein (AFP)	Lactate Dehydrogenase	coagulation (citrated) tube – this must he	(citrated) tube	-	Cocksfoot)	Hepatitis B surface Antigen (HBsAg)
Carcinoembryonic Ag (CEA)	NT Pro-BNP	done in house not referred to Enfer Medical.		Hepatitis B surface Antibody (Post vaccination)		
Androstenedione	Vitamin D	Enjer Wedicui.		Hepatitis C Antibody (anti-HCV core IgG)		
Lipid Profile (fasting)	Renal Profile			Hepatitis C PCR (HCV RNA; current infection)		
Liver Profile	Bone Profile			Syphilis serology		
Glucose (random)	Microalbumin – ACR			HIV Ag/An Combo assay		
Glucose (fasting)	Protein/Creatinine Ratio - PCR			Individual serology screens (HIV, Hep B, Hep C, Hep A)		
Glucose (2hr PP)	HbA1c			Individual Molecular screens (HSV PCR)		

Revision: 002 Date of Issue: 18/04/2025 Page: 23 of 78



APPENDIX 2: Specimen Stability/Collection Guidance, TATs and reference ranges for Approved Services for OLOLHD

Profile Analytes							
OLOLHD Ref.	Profile	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
				BONE PRO	FILE		
Calcium	Bone	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	Adult ≥ 18 years 0 to <1 year 1 year to < 18 years	2.10 to 2.55 2.13 to 2.74 2.29 to 2.63
Phosphate	Bone	5mL venous serum or plasma	Next working day	Specimens should be tested within 3 days of collection and stored at 2-8°C	mmol/L	Adult ≥ 18 years Female 0 to < 15 Days Female 15 Days to < 1 year Female 1 to < 5 years Female 5 to < 13 years Female 13 to < 16 years Female 16 to < 18 years Male 0 to < 15 Days Male 15 Days to < 1 year Male 1 to < 5 years Male 5 to < 13 years Male 15 to < 16 years Male 13 to < 16 years Male 13 to < 16 years	0.74 to 1.52 1.80 to 3.4 1.54 to 2.72 1.38 to 2.19 1.33 to 1.92 1.02 to 1.79 0.95 to 1.62 1.80 to 3.4 1.54 to 2.72 1.38 to 2.19 1.33 to 1.92 1.14 to 1.99 0.95 to 1.62

Revision: 002 Date of Issue: 18/04/2025 Page: 24 of 78



Albumin	Bone	5mL	Next	Specimens	g/L	Adult ≥18 years	35 to 50
		venous	working day	should be tested		Adult 60-90 years	32 to 46
		serum or		within 7 days of		Adult >90 years	29 to 45
		plasma		collection and		Female 0 to < 15 Days	28 to 41
				stored at 2-8°C.		Female 15 Days to < 1 year	25 to 46
						Female 1 to < 8 years	35 to 45
						Female 8 to < 15 years	37 to 47
						Female 15 to < 18 years	35 to 49
						Male 0 to < 15 Days	28 to 41
						Male 15 Days to < 1 year	25 to 46
						Male 1 to < 8 years	35 to 45
						Male 8 to < 15 years	37 to 47
						Male 15 to < 18 years	38 to 50
Adjusted	Bone	Adjusted	Calculation	Next working	Mmol/L	Adult ≥ 18 years	2.09 to 2.47
Calcium		Calcium		day			
				LIPID PRO	FILE		
Total	Lipid	5mL	Next	Specimens	mmol/L	Fasting	≤ 5.0
Cholesterol		venous	working day	should be tested		Non-Fasting	≤ 5.0
		serum or		within 7 days of		Female 0 to < 15 Days	1.2 to 3.23
		plasma		collection and		Female 15 Days to < 1 year	1.66 to 6.13
				stored at 2-8°C.		Female 1 to < 18 years	2.9 to 5.4
						Male 0 to < 15 Days Male 15 Days to < 1 year	1.1 to 2.82 1.66 to 6.13
						Male 15 Days to < 1 year	2.9 to 5.4
HDL	Lipid	5mL	Next	Specimens	mmol/L	Fasting Adult ≥ 18 years	1.0 to 2.0
_		venous	working day	should be tested	, =	Non-Fasting ≥ 18 years	1.0 to 2.0
		1 -11 - 11 -	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			: : ::::::: j = =:	

Revision: 002 Date of Issue: 18/04/2025 Page: 25 of 78



		serum or		within 7 days of		Female 0 to < 15 Days	0.4 to 1.08
		plasma		collection and		Female 15 Days to < 1 year	0.3 to 1.85
				stored at 2-8°C.		Female 1 to < 4 years	0.84 to 1.63
						Female 4 to < 13 years	0.92 to 1.88
						Female 13 to < 18 years	0.83 to 1.86
						Male 0 to < 15 Days	0.4 to 1.08
						Male 15 Days to < 1 year	0.3 to 1.85
						Male 1 to < 4 years	0.84 to 1.63
						Male 4 to < 13 years	0.92 to 1.88
						Male 13 to < 18 years	0.82 to 1.77
LDL	Lipid	5mL	Next	Specimens	mmol/L	Adult Fasting ≥ 18 years	≤ 3.0
		venous	working day	should be tested		Adult Non-Fasting ≥ 18 years	≤ 3.0
		serum or		within 7 days of		Female 0 to < 1 year	0.34 to 4.48
		plasma		collection and		Female 1 to < 10 years	1.52 to 3.32
				stored at 2-8°C.		Female 10 to < 18 years	1.18 to 3.4
						Male 0 to < 1 year	0.34 to 4.48
						Male 1 to < 10 years	1.22 to 3.14
						Male 10 to < 18 years	1.18 to 3.4
Triglycerides	Lipid	5mL	Next	Specimens	mmol/L	Fasting	≤ 1.7
		venous	working day	should be tested		Non-Fasting	≤ 2.0
		serum or		within 3 days of		0 to < 15 Days	0.93 to 2.93
		plasma		collection and		15 Days to < 1 year	0.6 to 2.92
				stored at 2-8°C.		1 to < 18 years	0.5 to 2.23
				LIVER PRO	FILE		
Total Protein	Liver	5mL	Next	Specimens	g/L	Adult ≥ 18 years	64 to 83
		venous	working day	should be tested		>60 years	62 to 81

Revision: 002 Date of Issue: 18/04/2025 Page: 26 of 78



		serum or		within 7 days of		0 to < 15 Days	53 to 83
		plasma		collection and		15 Days to < 1 year	44 to 71
				stored at 2-8°C.		1 to < 6 years	61 to 75
						6 to < 9 years	64 to 77
						9 to < 18 years	65 to 81
Albumin	Liver	5mL ľ	Next	Specimens	g/L	Adult ≥18 years	35 to 50
		venous v	working day	should be tested		Adult 60-90 years	32 to 46
		serum or		within 7 days of		Adult >90 years	29 to 45
		plasma		collection and		Female 0 to < 15 Days	28 to 41
				stored at 2-8°C.		Female 15 Days to < 1 year	25 to 46
						Female 1 to < 8 years	35 to 45
						Female 8 to < 15 years	37 to 47
						Female 15 to < 18 years	35 to 49
						Male 0 to < 15 Days	28 to 41
						Male 15 Days to < 1 year	25 to 46
						Male 1 to < 8 years	35 to 45
						Male 8 to < 15 years	37 to 47
						Male 15 to < 18 years	38 to 50
ALP	Liver	5mL ľ	Next	Specimens	U/L	Male >=18 to 21 years	56 to 167
		venous	working day	should be tested		Male ≥ 22 years	50 to 116
		serum or		within 7 days of		Male 0 to < 15 Days	90 to 273
		plasma		collection and		Male 15 Days to < 1 year	134 to 518
				stored at 2-8°C.		Male 1 to < 10 years	156 to 369
						Male 10 to < 13 years	141 to 460
						Male 13 to < 15 years	127 to 517
						Male 15 to < 17 years	89 to 365
						Male 17 to < 18 years	59 to 164
						Female >=18 - 29 years	44 to 107
						Female ≥30 years	46 to 122
						Female 0 to < 15 Days	90 to 273

Revision: 002 Date of Issue: 18/04/2025 Page: 27 of 78



ALT	Liver	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	U/L	Female 15 Days to < 1 year Female 1 to < 10 years Female 10 to < 13 years Female 13 to < 15 years Female 15 to < 17 years Female 17 to < 18 years Male 0 to < 1 year Male 1 to < 13 years Male 13 to < 18 years Male >=18 years Female 0 to < 1 year Female 1 to < 13 years Female >=18 years Female 3 to < 18 years Female 1 to < 18 years Female 1 to < 18 years	134 to 518 156 to 369 141 to 460 62 to 280 54 to 128 48 to 95 5 to 33 9 to 25 9 to 24 <45 5 to 33 9 to 25 8 to 22 <34
GGT	Liver	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	U/L	Male Adult ≥ 18 years Female Adult ≥ 18 years 0 to < 15 Days 15 Days to < 1 year 1 to < 11 years 11 to < 18 years	12 to 64 9 to 36 23 to 219 8 to 127 6 to 16 7 to 21
Total Bilirubin	Liver	5mL venous serum or plasma	Next working day	Specimens should be tested within 3 days of collection and stored at 2-8°C.	μmol/L	Adult ≥ 18 years 0 to < 15 Days 15 Days to < 1 year 1 to < 9 years 9 to < 12 years	3.4 to 20.5 3 to 284 1 to 12 1 to 7 1 to 9

Revision: 002 Date of Issue: 18/04/2025 Page: 28 of 78



						12 to < 15 years 15 to < 18 years	2 to 12 2 to 14
Globulin	Liver	5mL venous serum or plasma	Next working day	Specimens should be tested within 6 days of collection and stored at 2-8°C.	g/L	18 to 150 years	20 to 35
			1	RENAL PRO	OFILE		
Sodium	Renal	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	Adult ≥ 18 years <18 years	136 to 145 133 to 146
Chloride	Renal	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	Adult ≥ 18 years <18 years	98 to 107 95 to 106
Urea	Renal	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	Male <50 years Male >50 years Female <50 years Female >50 years Female > 50 years	3.2 to 7.4 3.0 to 9.2 2.5 to 6.7 3.5 to 7.2 1.0 to 8.2

Revision: 002 Date of Issue: 18/04/2025 Page: 29 of 78



						Female 15 Days to < 1 year	1.2 to 6
						Female 1 to < 10 years	3.2 to 7.9
						Female 10 to < 18 years	2.6 to 6.8
						Male 0 to < 15 Days	1.0 to 8.2
						Male 15 Days to < 1 year	1.2 to 6
						Male 1 to < 10 years	3.2 to 7.9
						Male 10 to < 18 years	2.6 to 7.5
Creatinine	Renal	5mL	Next	Specimens	μmol/L	Female Adult ≥ 18 years	49 to 90
		venous	working day	should be tested		Female 0 to <15 days	29 to 82
		serum or		within 7 days of		Female 15 days to <2 years	9 to 32
		plasma		collection and		Female 2 to <5 years	18 to 38
				stored at 2-8°C.		Female 5 to <12 years	27 to 54
						Female 12 to < 15 years	40 to 72
						Female 15 to < 18 years	43 to 74
						Male Adult ≥ 18 years	64 to 104
						Male 0 to <15 days	29 to 82
						Male 15 days to <2 years	9 to 32
						Male 2 to <5 years	18 to 38
						Male 5 to <12 years	27 to 54
						Male 12 to < 15 years	40 to 72
						Male 15 to < 18 years	55 to 96
eGFR	Renal	5mL	Next	Specimens	mL/min/1.73m2	≥18 years	60-150
		venous	working day	should be tested			
		serum or		within 7 days of			
		plasma		collection and			
				stored at 2-8°C.			
						<18 years	90 to 150

Revision: 002 Date of Issue: 18/04/2025 Page: 30 of 78



	IRON STUDIES/IBC PROFILE										
Iron	Iron Studies	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	µmol/L	Male Adult ≥ 18 years Female Adult ≥ 18 years Female 0 to < 14 years Female 14 to < 18 years Male 0 to < 14 years Male 14 to < 18 years	11.6 to 31.2 9.0 to 30.4 2.8 to 22.9 3.5 to 29.0 2.8 to 22.9 5.5 to 30.0				
Ferritin	Iron Studies	5mL venous serum	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	ng/mL	Female Adult ≥ 18 years Female 4 to 14 Days Female 15 Days to < 6 Months Female 6 Months to < 1 year Female 1 to < 5 years Female 5 to < 14 years Female 14 to < 18 years Male Adult ≥ 18 years Male 4 to 14 Days Male 15 Days to < 6 Months Male 6 Months to < 1 year Male 1 to < 5 years Male 1 to < 5 years Male 1 to < 14 years Male 1 to < 18 years Male 5 to < 14 years Male 5 to < 14 years Male 14 to < 16 years Male 16 to < 18 years	4.6 to 204.0 99.6 to 717.0 14.0 to 647.2 8.4 to 181.9 5.3 to 99.9 13.7 to 78.8 5.5 to 67.4 21.8 to 274.7 99.6 to 717.0 14.0 to 647.2 8.4 to 181.9 5.3 to 99.9 13.7 to 78.8 12.7 to 82.8 11.1 to 171.9				
TIBC	Iron Studies	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	µmol/L	All ages	45 to 91				

Revision: 002 Date of Issue: 18/04/2025 Page: 31 of 78



Transferrin	Iron Studies	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and	mg/dL	Male 18 to 60 years Male 61 to 80 years Female 18 to 60 years Female 61 to 80 years	174 to 364 163 to 344 180 to 382 173 to 360
				stored at 2-8°C.		0 to < 9 Weeks 9 Weeks to < 1 year 1 to < 18 years	104 to 224 107 to 324 220 to 337
Transferrin Saturation	Iron Studies	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	%	Males ≥ 18 years Females ≥ 18 years Female 0 to < 1 year Female 1 to < 14 years Female 14 to < 18 years Male 0 to < 1 year Male 1 to < 14 years Male 1 to < 14 years	≤50 % ≤45 % 4.1 to 59 6.5 to 39 5.2 to 44 4.1 to 59 6.5 to 39 9.6 to 58
				LH/FS	н		
FSH	LH/FSH	5mL venous serum	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mIU/mL	Male Adult ≥ 18 years Adult Follicular Phase Adult Ovulatory Phase Adult Luteal Phase Adult Post-menopause Female 30 Days to < 1 year Female 1 to < 9 years Female 9 to < 11 years Female 11 to < 18 years	1.27 to 19.26 3.85 to 8.78 4.54 to 22.51 1.79 to 5.12 16.74 to 113.59 0.38 to 10.4 0.42 to 5.45 0.44 to 4.22 0.26 to 7.77

Revision: 002 Date of Issue: 18/04/2025 Page: 32 of 78



						Male 30 Days to < 1 year	0.09 to 2.41
						Male 1 to < 5 years	0 to 0.91
						Male 5 to < 10 years	0 to 1.62
						Male 10 to < 13 years	0.35 to 3.91
						Male 13 to < 18 years	0.78 to 5.1
LH	LH/FSH	5mL	Next	Specimens	mIU/MI	Male Adult ≥ 18 years	1.24 to 8.62
		venous	working day	should be tested		Adult Follicular Phase	2.12 to 10.89
		serum		within 7 days of		Adult Mid-Cycle	19.16 to 103.03
				collection and		Adult Luteal Phase	1.20 to 12.86
				stored at 2-8°C.		Adult Post-menopause	10.87 to 58.64
						Female 4 Days to < 3 Months	0 to 2.41
						Female 3 Months to < 1 year	0 to 1.19
						Female 1 to < 10 years	0 to 0.33
						Female 10 to < 13 years	0 to 4.34
						Female 13 to < 15 years	0.37 to 6.52
						Female 15 to < 17 years	0 to 13.1
						Female 17 to < 18 years	0 to 8.38
						Male 4 Days to < 3 Months	0.19 to 3.81
						Male 3 Months to < 1 year	0 to 2.89
						Male 1 to < 10 years	0 to 0.33
						Male 10 to < 13 years	0 to 4.34
						Male 13 to < 15 years	0 to 4.11
						Male 15 to < 17 years	0.79 to 4.76
						Male 17 to < 18 years	0.94 to 7.1

Revision: 002 Date of Issue: 18/04/2025 Page: 33 of 78



			VITAMIN B	12 & FOLATE	FASTING	PROFILE	
Vitamin B12	Vit12 &	5mL	Next	Specimens	pg/ml	Adult ≥ 18 years	187 to 883
	Folate Profile	venous	working day	should be tested		5 days to <1 year	259 to 1576
		serum		within 3 days of		1 year to < 9 years	283 to 1613
				collection and		9 to < 14 years	252 to 1125
				stored at 2-8°C.		14 to < 17 years	244 to 888
						17 to < 18 years	203 to 811
Folate	Vit12 &	5mL	Next	Specimens	ng/mL	Adult ≥ 18 years	3.1 to 20.0
	Folate Profile	venous	working day	should be tested		5 Days to < 1 year	10.6 to 45.3
		serum		within 7 days of		1 to < 3 years	3.9 to 45.3
				collection and		3 to < 6 years	11.9 to 45.3
				stored at 2-8°C.		6 to < 8 years	13.1 to 45.3
						8 to < 12 years	11.4 to 45.3
						12 to < 14 years	11.9 to 45.3
						14 to < 18 years	7.9 to 45.3
				TFT PROF	ILE		
TSH	TFT	5mL	Next	Specimens	mIU/L	Adult ≥ 18 years	0.35 to 4.94
		venous	working day	should be tested		4 Days to < 6 Months	0.73 to 4.77
		serum		within 7 days of		6 Months to < 14 Years	0.70 to 4.17
				collection and		14 to < 18 Years	0.47 to 3.41
				stored at 2-8°C.			
FT4	TFT	5mL	Next	Specimens	pmol/L	Adult ≥ 18 years	9.01 to 19.05
		venous	working day	should be tested		0 to <1 year	10.5 to 18.8
		serum		within 6 days of		1 to <18 years	9.98 to 14.29
				collection and			
				stored at 2-8°C.			

Revision: 002 Date of Issue: 18/04/2025 Page: 34 of 78



			CTD - Co	nnective Tissu	ie Disease	Screen	
ANAB	CTD Screen	5mL venous serum	3 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	IU/mL	N/A	Pos/Neg
DNAA	CTD Screen	5mL venous serum	3 working days	Specimens should be tested within 14 days of collection and stored at 2-8°C.	IU/mL	N/A	<10 Negative
ENA	CTD Screen	5mL venous serum	3 working days	Specimens should be tested within 14 days of collection and stored at 2-8°C.	IU/mL	N/A	Pos/Neg

Revision: 002 Date of Issue: 18/04/2025 Page: 35 of 78



Clinical Chemistry Analytes

OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
25-OH Vitamin D2 and	5mL venous	Next working	Specimens	nmol/L	Adult ≥ 18 years	50 to 125
D3 (please include	serum	day	should be tested		5 to 14 Days	4.25 to 85
clinical indications on			within 3 days of		15 Days to < 3 Months	15.4 to 101
the patient test request			collection and		3 Months to < 1 year	17.3 to 118
form) per section 10.0			stored at 2-8°C.		1 to < 9 years	33.1 to 137
above					9 to < 14 years	31.7 to 116
					14 to < 18 years	12 to 106
Adjusted Calcium	Calculation	Next working day	NA	Mmol/L	Adult ≥ 18 years	2.09-2.47
Alpha-fetoprotein (AFP)	5mL venous	Next working	Specimens	ng/mL	Adult ≥ 18 years	0.89 to 8.78
	serum	day	should be tested		0 to < 1 Month	0 to 2000
			within 7 days of		1 to < 6 Months	9.8 to 1359
			collection and		6 Months to < 1 year	0.4 to 103.1
			stored at 2-8°C.		1 to < 18 years	0.8 to 34.8
Anti Mullerian Hormone	5mL venous	Next working	Specimens	pmol/L	Female 18-25 years	6.82 to 95.22
(AMH)	serum	day	should be tested		Female 26-30 years	1.22 to 52.66
			within 6 days of		Female 31-35 years	0.53 to 52.48
			collection and		Female 36-40 years	0.20 to 51.03
			stored at 2-8°C.		Female 41-45 years	0.00 to 23.35
					Female ≥ 46 years	0.00 to 8.19
					Female 0 to 28 days	≤ 6.7
					Female 29 days to <1 year	≤ 31.2

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons

Revision: 002 Date of Issue: 18/04/2025 Page: 36 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
					Female 1 to <5 years	1.3 to 43.7
					Female 5 to <8 years	1.4 to 39.5
					Female 8 to <12 years	2.9 to 52.8
					Female 12 to <15 years	3.0 to 46.6
					Female 15 to <18 years	2.1 to 84.1
					Male 0 to 2 days	68.0 to 523.7
					Male 3 to 7 days	138.3 to 1023.7
					Male 8 to 10 days	195.2 to 1200.9
					Male 11 to 20 days	140.1 to 1130.9
					Male 21-28 days	212.0 to 951.4
					Male 29 days to <1 year	203.8 to 971.7
					Male 1 to <5 years	268.6 to 1229.9
					Male 5 to <8 years	206.2 to 956.5
					Male 8 to <12 years	84.0 to 976.4
					Male 12 to <15 years	8.8 to 286.8
					Male 15 to <18 years	16.8 to 130.0
					Males ≥ 18 years	5.20 to 114.60
Amylase	5mL venous	Next working	Specimens	U/L	Adults 18-70 years	25 to 125
	serum or plasma	day	should be tested		Adults ≥70 years	20 to 160
			within 7 days of		1-18 years	25 to 101
			collection and		13 weeks to <1 year	3 to 50
			stored at 2-8°C.		15 days to <13 weeks	2 to 22
					0 to <15 days	3 to 10
Thyroid microsomal antibodies (Anti-TPO)	5mL venous serum	Next working day	Specimens must be spun within 8 hours and be	IU/mL	0 to 150 years	< 5.61
			tested within 3			

Revision: 002 Date of Issue: 18/04/2025 Page: 37 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Anti-TG (Anti Thyroglobulin antibody)	5mL venous serum	Next working day	days of collection and stored at 2-8°C. Remove serum from clot or separator gel if testing will be delayed more than 8 hours. Specimens must be spun within 8 hours and be tested within 3 days of collection and stored at 2-8°C. Remove serum from clot or separator gel	IU/mL	Adult ≥ 18 years <18 years	< 4.11 0.4 to 17.7
AST	5mL venous	Next working	if testing will be delayed more than 8 hours. Specimens should be tested	U/L	Adult > 18 years Female 0 to < 15 Days	5 - 34 32 to 162
	serum or plasma	day	within 7 days of collection and stored at 2-8°C.		Female 0 to < 15 Days Female 15 Days to < 1yr Female 1 to < 7 years Female 7 to < 12 years Female 12 to < 18 years Male 0 to < 15 Days Male 15 Days to < 1 year	20 to 67 21 to 44 18 to 36 13 to 26 32 to 162 20 to 67

Revision: 002 Date of Issue: 18/04/2025 Page: 38 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
					Male 1 to < 7 years	21 to 44
					Male 7 to < 12 years	18 to 36
					Male 12 to < 18 years	14 to 35
Beta-HCG	5mL venous	Next working	Specimens	IU/L	Adult ≥ 18 years	<5
Deta fied	serum	day	should be tested	10/2	Female 0-3 months	≤50
	Scram	day	within 7 days of		Female > 3months to <18 yrs	<1.0
			collection and		Male 0-3 months	≤50
			stored at 2-8°C.		Male > 3months to <18 years	<1.4
Bicarbonate (CO2)	5mL venous	Next working	Specimens must	Mmol/L	Adult ≥ 18 years	22 to 29
	serum or plasma	day	be tested within		Adult > 60 years	23 to 31
			3 days of		Female 0 to <15 days	5 to 20
			collection and		Female 15 days to <1 year	10 to 24
			stored at 2-8°C.		Female 1 to <5 years	14 to 24
					Female 5 to <15 years	17 to 26
					Female 15 to < 18 years	17 to 26
					Male 0 to <15 days	5 to 20
					Male 15 days to <1 year	10 to 24
					Male 1 to <5 years	14 to 24
					Male 5 to <15 years	17 to 26
					Male 15 to < 18 Years	18 to 28

Revision: 002 Date of Issue: 18/04/2025 Page: 39 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
CA-125	5mL venous	Next working	Specimens	U/mL	Female ≥ 18 years	≤35.0
	serum	day	should be tested		Female 0 to < 4 Months	2.4 to 22
			within 7 days of		Female 4 Months to < 5 years	7.7 to 33
			collection and		Female 5 to < 11 years	4.7 to 30
			stored at 2-8°C.		Female 11 to < 18 years	5.9 to 39
					Male 0 to < 4 Months	2.4 to 22
					Male 4 Months to < 5 years	7.7 to 33
					Male 5 to < 11 years	4.7 to 30
					Male 11 to < 18 years	5.4 to 28
CA15-3	5mL venous	Next working	Specimens	U/mL	Adult ≥ 18 years	≤31.3
	serum	day	should be tested		0 to < 1 Week	3.4 to 24
			within 7 days of		1 Week to < 1 year	4.9 to 33
			collection and		1 to < 18 years	3.9 to 21
			stored at 2-8°C.			
CA19-9	5mL venous	Next working	Specimens	U/mL	Adult ≥ 18 years	≤ 37
	serum	day	should be tested		0 to < 1 year	0 to 64
			within 7 days of		1 to < 18 years	0 to 41
			collection and			
			stored at 2-8°C.			
Calprotectin	QFIT	3-6 working	Specimens	ug/g	Adult ≥ 18 years	<50 ug/g
		days	should be tested			50-250 ug/g
			within 28 days of			100 - 250 ug/g
			collection and			>250 ug/g
			stored at 2-8°C.			

Revision: 002 Date of Issue: 18/04/2025 Page: 40 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Carbamazepine	5mL venous serum	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mg/L	Adults ≥ 18 years	In combination with other anti convulsants: 4-8mg/L If prescribed on its own 6-12mg/L
Carcinoembryonic Antigen (CEA)	5mL venous serum	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C. Specimens Should be tested within 24 hours if unspun.	ng/ml	Adult ≥ 18 years 0 to < 1 Week 1 Week to < 2 years 2 to < 18 years	≤5.00 8.1 to 62 8.1 to 62 0 to 2.6
Creatinine Kinase (CK)	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	U/L	Male Adult ≥ 18 years Female Adult ≥ 18 years <18 years	30 to 200 29 to 168 25 to 300
Cortisol	5mL venous serum	Next working day	Specimens must be spun within 8 hours and tested within 7 days of collection and stored at 2-8°C. Remove serum from clot or	nmol/L	Adult ≥ 18 Before 10am collection Adult ≥ 18 After 5pm collection 2 to < 15 Days 15 Days to < 1 year 1 to < 9 years 9 to < 14 years	102.1 to 535.2 80.0 to 477.3 13.1 to 339.5 14.3 to 458.1 47.8 to 297 60.5 to 349.2

Revision: 002 Date of Issue: 18/04/2025 Page: 41 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
			separator gel if testing will be delayed more than 8 hours.		14 to < 17 years 17 to < 18 years	76.9 to 452.5 97 to 505.7
Digoxin	5mL venous serum SST	1-2 working days	Specimens should be tested within 14 days of collection and stored at 2-8°C.	ug/L	Adult ≥ 18 years	0.5-2.0
Folate	5mL venous serum	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	ng/mL	Adult ≥ 18 years 5 Days to < 1 year 1 to < 3 years 3 to < 6 years 6 to < 8 years 8 to < 12 years 12 to < 14 years 14 to < 18 years	3.1 to 20.0 10.6 to 45.3 3.9 to 45.3 11.9 to 45.3 13.1 to 45.3 11.4 to 45.3 11.9 to 45.3 7.9 to 45.3

Revision: 002 Date of Issue: 18/04/2025 Page: 42 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
FSH	5mL venous	Next working	Specimens	mIU/mL	Male Adult ≥ 18 years	1.27 to 19.26
	serum	day	should be tested		Adult Follicular Phase	3.85 to 8.78
			within 7 days of		Adult Ovulatory Phase	4.54 to 22.51
			collection and		Adult Luteal Phase	1.79 to 5.12
			stored at 2-8°C.		Adult Post-menopause	16.74 to 113.59
					Female 30 Days to < 1 year	0.38 to 10.4
					Female 1 to < 9 years	0.42 to 5.45
					Female 9 to < 11 years	0.44 to 4.22
					Female 11 to < 18 years	0.26 to 7.77
					Male 30 Days to < 1 year	0.09 to 2.41
					Male 1 to < 5 years	0 to 0.91
					Male 5 to < 10 years	0 to 1.62
					Male 10 to < 13 years	0.35 to 3.91
					Male 13 to < 18 years	0.78 to 5.1
FT3 Free T3	5mL venous	Next working	Specimens must	Pmol/L	Adult ≥ 18 years	2.43 to 6.00
	serum	day	be tested within		Female 4 Days to < 1 year	3.56 to 7.48
			6 days of		Female 1 to < 12 years	4.29 to 6.79
			collection and		Female 12 to < 15 years	3.84 to 6.06
			stored at 2-8°C.		Female 15 to < 18 years	3.55 to 5.7
					Male 4 Days to < 1 year	3.56 to 7.48
					Male 1 to < 12 years	4.29 to 6.79
					Male 12 to < 15 years	4.44 to 6.65
					Male 15 to < 18 years	3.46 to 5.92

Revision: 002 Date of Issue: 18/04/2025 Page: 43 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Glucose	5mL venous sodium fluoride/potassium oxalate plasma	Next working day	Specimens Should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	Fasting Adult ≥ 18 years Fasting <4 weeks Fasting 4 weeks to <18 years	4.0 to 7.0 2.5 to 5.5 3.0 to 6.0
Glucose Tolerance	X2 5mL venous sodium fluoride/potassium oxalate plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	Two-hour plasma glucose concentration two hours after 75g anhydrous glucose in an oral glucose tolerance test (OGTT) Gestational Diabetes	Normal <7.8 Impaired glucose tolerance 7.8-11.1 Diabetes >11.1
Haemochromatosis Genetic Screen	EDTA 4ml/6ml (6ml EDTA tubes are used for specific PCR assays). Clinical History must be provided.	1 – 4 working days	Specimens must be tested within 14 days of collection.	N/A	N/A	N/A
HbA1c	5mL Whole blood EDTA	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/mol	Adults ≥ 18 years <18 years	<42 20 to 42

Revision: 002 Date of Issue: 18/04/2025 Page: 44 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
High Sens. CRP	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mg/L	Adult ≥ 18 years 0 to <15 days 15 days to < 15 years 15 to <18 years	≤5 0.3 to 6.1 0.1 to 1 0.1 to 1.7
LDH	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	U/L	Adult ≥ 18 years Female 0 to < 15 Days Female 15 Days to < 1 year Female 1 to < 10 years Female 10 to < 15 years Female 15 to < 18 years Male 0 to < 15 Days Male 15 Days to < 1 year Male 1 to < 10 years Male 1 to < 10 years Male 10 to < 15 years	125 to 220 309 to 1222 163 to 452 192 to 321 157 to 272 130 to 250 309 to 1222 163 to 452 192 to 321 170 to 283 130 to 250
Lithium	5mL venous serum or plasma (Sodium heparin K2 EDTA)	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	Trough Toxicity	1.00 to 1.20 0.6 to 1.50
Magnesium	5mL venous serum or plasma	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mmol/L	18-20 years Adult > 20 years 0 to < 15 Days 15 Days to < 1 year 1 to < 18 years	0.7 to 0.91 0.66 to 1.07 0.82 to 1.62 0.81 to 1.27 0.86 to 1.17
Microalbumin	Urine (MSU)	Next working day	Specimens should be tested	mg/L	0 to 150 years	<30

Revision: 002 Date of Issue: 18/04/2025 Page: 45 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
			within 6 days of			
			collection and			
			stored at 2-8°C.			
Oestradiol	5mL venous	Next working	Specimens	pmol/L	Male ≥18 years	88 to 161.52
	serum	day	should be tested		Adult Follicular Phase	88 to 921.42
			within 7 days of		Adult Ovulatory Phase	139.50 to 2382.48
			collection and		Adult Luteal Phase	88 to 1145.35
			stored at 2-8°C.		Adult Post-menopause	88 to 102.79
					Female 15 days to <1 year	0 to 25
					Female 1 to < 9 years	0 to 10
					Female 9 to < 11 years	0 to 48
					Female 11 to < 12 years	0 to 94
					Female 12 to < 14 years	11 to 172
					Female 14 to < 18 years	0 to 255
					Male 15 days to < 1 year	0 to 25
					Male 1 to < 11 years	0 to 13
					Male 11 to < 13 years	0 to 26
					Male 13 to < 15 years	0 to 28
					Male 15 to < 18 years	0 to 38
Phenytoin	5mL venous serum SST	1-2 working days	Specimens should be tested within 4 days of collection and stored at 2-8°C.	mg/l	Adult ≥ 18 years	40-80mg/l
Potassium*	5mL venous serum	Next working day if	Sample must be centrifuged at	mmol/L	Adult ≥ 18 years Serum	3.5 to 5.1
		centrifuged at			Adult ≥ 18 years Male Plasma	3.5 to 4.5

Revision: 002 Date of Issue: 18/04/2025 Page: 46 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
		3500rpm for 10	3500rpm for 10			
		minutes within 4	minutes		Adult ≥ 18 years Female	3.4 to 4.4
		hours of sample	It is critical to		Plasma	
		collection	include the			3.5 to 5.5
			following details		<18 years Serum	
			on the PRF			
			(Patient Request			
			Form) to ensure			
			the sample			
			meets testing			
			criteria:			
			 Centrifuge 			
			Speed			
			(3500rpm)			
			 Centrifuge 			
			Duration (10			
			minutes)			
			Time of			
			Centrifugation			
			(specific time the			
			centrifugation			
			process was			
			completed)			
Pro-BNP*	5mL venous	Next working	Specimens must	pg/ml	Adult ≥ 75 years	≤ 125.0
	serum	day	be spun within		Adult<75 years	≤ 450.0
			24 hours and		<18 years	≤ 300
			tested within 6			
			days of collection			

Revision: 002 Date of Issue: 18/04/2025 Page: 47 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
			and stored at 2-			
			8°C. Remove			
			serum from clot			
			or separator gel			
			if testing will be			
			delayed more			
			than 24 hours			
Progesterone	5mL venous	Next working	Specimens	nmol/L	Male Adult ≥ 18 years	<1.60
	serum	day	should be tested		Follicular Phase	<1.60
			within 7 days of		Luteal Phase	3.82 to 50.56
			collection and		Post-menopause	<1.60
			stored at 2-8°C.		1st Trimester Pregnancy	8.90 to 468.41
					2nd Trimester Pregnancy	71.55 to 303.05
					3rd Trimester Pregnancy	88.72 to 771.15
					Female 4 Days to < 1 year	0 to 4.2
					Female 1 to < 10 years	0 to 1.1
					Female 10 to < 15 years	0.4 to 2.7
					Female 15 to < 18 years	0.64 to 32.62
					Male 30 Days to < 1 year	0 to 2.1
					Male 1 to < 10 years	0 to 1.1
					Male 10 to < 15 years	0.4 to 2.7
					Male 15 to < 18 years	0.5 to 1.8
Prolactin	5mL venous	Next working	Specimens	mIU/L	Males ≥ 18 years	72.66 to 407.40
	serum	day	should be tested		Females ≥ 18 years	108.78 to 557.13
			within 7 days of		0 to <1 year	115 to 1342
			collection and		1 to <18 years	72 to 592
			stored at 2-8°C.			

Revision: 002 Date of Issue: 18/04/2025 Page: 48 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
			Early morning or fasting specimens are preferable			
TPSA	5mL venous serum	Next working day	Specimens should be tested within 7 day of collection and stored at 2-8°C.	ng/mL	Adult <50 years 50-59 years 60-69 years ≥ 70 years Female 0 to < 1 Week Female 1 Week to < 1 year Female 1 to < 18 years Male 0 to < 1 Week Male 1 Week to < 6 Months Male 6 Months to < 12 years Male 12 to < 18 years	< 2.00 <3.00 <4.00 <5.00 0 to 0.039 0 to 0.01 0 to 0.015 0 to 0.047 0 to 0.038 0 to 0.353 0 to 0.566
Rheumatoid Factor	5mL venous serum	Next working day	Specimens should be tested within 8 days of collection and stored at 2-8°C.	IU/mL	Adult ≥ 18 years	<14.0 IU/mL
Uric Acid (Urate)	5mL venous serum or plasma	Next working day	Specimens should be tested within 3 days of collection and stored at 2-8°C.	µmol/L	Male Adult ≥ 18 years Female Adult ≥ 18 years Female 0 to < 15 Days Female 15 Days to < 1 year Female 1 to < 12 years Female 12 to < 18 years Male 0 to < 15 Days Male 15 Days to < 1 year	220 to 450 150 to 370 164 to 757 94 to 377 106 to 289 153 to 349 164 to 757 94 to 377

Revision: 002 Date of Issue: 18/04/2025 Page: 49 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
					Male 1 to < 12 years	106 to 289
					Male 12 to < 19 years	156 to 454
Urinary Creatinine	Urine – 30ml aliquot from 24 hr collection – state	Next working day	Specimens should be tested within 6 days of	umol/L	Male Adult ≥ 18 years	5.1-14.2mmol/L (1st morning urine)
	total volume		collection and stored at 2-8°C.		Female Adult ≥ 18 years	3.9-9.4mmol/L (1st morning urine)
Urinary Protein	Urine – 30ml aliquot from 24 hr collection – state total volume	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	g/L, g/24hr	Adult ≥ 18 years	10-140 mg/24hr
Valproic Acid (Valproate)	5mL venous serum SST	1-2 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mg/L	Adult ≥ 18 years	50-100mg/L
Sex Hormone Binding Globulin	5mL venous serum	Next working day	Specimens should be tested within 7 days of collection and stored at 2-8°C.	nmol/L	Female ≥ 18 years Female 4 Days to < 1 Month Female 1 Month to < 1 year Female 1 to < 8 years Female 8 to < 11 years Female 11 to < 13 years Female 13 to < 15 years Female 15 to < 17 years Female 17 to < 18 years	19.8 to 155.2 14.4 to 120 36.2 to 229 41.8 to 189 26.4 to 162 14.9 to 108 11.2 to 98.2 9.8 to 84.1 10.8 to 155

Revision: 002 Date of Issue: 18/04/2025 Page: 50 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
					Male 4 Days to < 1 Month	14.4 to 120
					Male 1 Month to < 1 year	36.2 to 229
					Male 1 to < 8 years	41.8 to 189
					Male 8 to < 11 years	26.4 to 162
					Male 11 to < 13 years	14.9 to 108
					Male 13 to < 15 years	11.2 to 98.2
					Male 15 to < 18 years	9.7 to 49.6
					Male ≥ 18 years	13.5 to 71.4
Testosterone	5mL venous	Next working	Specimens	nmol/L	Male 18 to 49 years	8.33 to 30.19
	serum	day	should be tested		Male ≥ 50 years	7.66 to 24.82
			within 7 days of		Female 18 to 49 years	0.48 to 1.85
			collection and		Female ≥ 50 years	0.43 to 1.24
			stored at 2-8°C.		Female 4 Days to < 9 years	0.04 to 2.15
					Female 9 to < 13 years	0 to 0.98
					Female 13 to < 15 years	0.36 to 1.54
					Female 15 to < 18 years	0.49 to 1.7
					Male 4 Days to < 6 Months	0.3 to 10.4
					Male 6 Months to < 9 year	0 to 1.24
					Male 9 to < 11 years	0 to 0.81
					Male 11 to < 14 years	0 to 15.4
					Male 14 to < 16 years	1.25 to 21.9
					Male 16 to < 18 years	5.13 to 27.6
Protein/Creatinine Ratio	As above.	Next working	Specimens	mg/mmol	Adult ≥ 18 years	0-45mg/mmol
	Random Urine.	day	should be tested			
			within 6 days of			
			collection and			
			stored at 2-8°C.			

Revision: 002 Date of Issue: 18/04/2025 Page: 51 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Microalbumin/Creatinine Ratio	As above. Random Urine.	Next working day	Specimens should be tested within 6 days of collection and stored at 2-8°C.	mg/mmol	Adult ≥ 18 years	0-2.9mg/mmol
Androstenedione	5mL venous serum	1-6 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	nmol/L	Adult ≥ 18 years	Male 1.5 - 6.5 Female 0.0 - 10.1
Phenobarbitone	5mL venous serum	1-2working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mg/L	Adult ≥ 18 years	10-30mg/L
Theophylline	5mL venous serum	1-2 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mg/L	Age 0 - 30d Other	28 - 70 55 - 111
Carbenamazapine	5mL venous serum	1-2 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	mg/L	N/A	In combination with other anti convulsants: 4-8mg/L If prescribed on its ownL 6-12mg/L

Revision: 002 Date of Issue: 18/04/2025 Page: 52 of 78



OLOLHD Ref.	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
						Should be managed
						according to local
						guidelines

^{*} Time-sensitive tests that must be performed in accordance with testing protocols.

Haematology Analytes

Test	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Coagulation Screen*	Sodium Citrate	Next	Specimens should	Seconds		PT
(PT/INR)	Plasma	working day	be tested within		Up to 5yrs	10.6 - 11.4
			24 hours of		5 to 10yrs	10.1 - 12.1
			collection and		10 to 16yrs	10.2 - 12.0
			stored at room		17 to 99yrs	10.8 - 13.9
			temperature.			
INR*	Sodium Citrate	Next	Specimens should	Ratio	0 - 99 yrs	INR
	Plasma	working day	be tested within			Non anticoagulated 1.0-1.3
			24 hours of			
			collection and			
			stored at room			
			temperature.			
ESR*	Whole blood	Next	Specimens should	mm/hr	<16 years	1- 13mm/hr
	EDTA	working day	be tested within			
			24 hours of		Male 17- 70 yrs	≤ 15mm/hr
			collection and			
			stored at 2-8°C.			≤ 20mm/hr

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 53 of 78



Test	Specimen	Turnaround	Stability and	Units	Demographics	Reference R	ange
	Туре	Time	Storage				
			Specimens over		Female 17- 70		
			24hrs and under		years		
			48hrs can be			≤ 30mm/hr	
			tested but will be		Male > 70		
			reported with a			≤ 35mm/hr	
			test comment.		Female > 70		
FBC & Differential	Whole blood	Next	Specimens should	<u>Parameter</u>	Adults >18 yrs	Adult Male	<u>Adult</u>
	EDTA	working day	be tested within 3	Red Blood		<u>Female</u>	
			days of collection	Count		4.5-5.5	3.8-4.8
			and stored at 2-	(10^12/L)			
			8°C.				
				Haemoglobin			
				(g/dL)		13.0-17.0	12.0-15.0
				I I a a sea a ba a seib			
				Haematocrit		0.40.0.50	0.26.0.46
				(L/L)		0.40-0.50	0.36-0.46
				Mean Cell			
				Volume (fL)		Male and Fem	nale (>18)
						83-101	
				Mean cell			
				haemoglobin			
				(pg)		27-32	
				Mean cell			
				haemoglobin			
				concentration		31.5-34.5	
				(g/dL)			

Revision: 002 Date of Issue: 18/04/2025 Page: 54 of 78



Test	Specimen	Turnaround	Stability and	Units	Demographics	Reference Range
	Туре	Time	Storage			
				Red-cell		
				distribution		
				width (%)		11.6-14
				(10)		
				Red-cell		
				distribution		
				width (fL)		39-46
				Platelet		
				count		150-410
				(10^9/L)		150-410
				White blood		
				cell count		
				(10^9/L)		4.0-10.0
				Neutrophil		
				count		
				(10^9/L)		2.0-7.0
				Lymphocyto		
				Lymphocyte count		
				(10^9/L)		1.0-3.0
				(10)/[/		1.0 0.0
				Monocyte		

Revision: 002 Date of Issue: 18/04/2025 Page: 55 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
				count (10^9/L)		0.2-1.0
				Eosinophil count (10^9/L)		0.02-0.5
				Basophil count (10^9/L)		0.02-0.1
				Reticulocyte count (10^9/L)		50-100
				NRBC count (10^9/L)		0
				Neutrophil percent (%)		40-80
				Lymphocyte percent (%)		20-40
				Monocyte percent (%)		2.0-10.0

Revision: 002 Date of Issue: 18/04/2025 Page: 56 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
				Eosinophil percent (%)		1.0-6.0
				Basophil percent (%)		0.01-2.0
				Reticulocyte percent (%)		0.5-2.5
				NRBC percent (%)		0
Blood Film	Whole blood EDTA	1-3 working days from FBC result	Specimens should be tested within 24 hours of collection and stored at 2- 8°C.	N/A	All ages	N/A
Ferritin	5mL venous serum	Next working day	Specimens should be tested within 7 days of collection and stored at 2- 8°C.	ng/mL	See test specific ranges	See test specific ranges
Sickle Cell Screen/Thalassaemia	Whole blood EDTA	1-5 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	Qualitative (%, pg, fL, and x10^12/L)	See appendix 2.1	See appendix 2.1

Revision: 002 Date of Issue: 18/04/2025 Page: 57 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
G6PD	5ml EDTA Plasma	1-5working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.	U/g Hb	Adult ≥ 18 years	5.6 - 11.2 U/g Hb
Infectious Mononucleosis (Monospot)	5ml EDTA Plasma	Next working day	Specimens should be tested within 6 days of collection and stored at 2- 8°C.	Detected/ Not Detected/ Invalid	NA	NA

^{*}Time-sensitive tests that must be performed in accordance with testing protocols.

Revision: 002 Date of Issue: 18/04/2025 Page: 58 of 78



Immunology Analytes

Test	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Tissue Transglutaminase antibody (TTG IgA)	5mL venous serum	1-3 working days	Specimens should be tested within 14 days of collection and stored at 2-8°C.	U/mL	N/A	0U/mL-10U/mL Coeliac disease unlikely (please note that if the patient has no dietary gluten results may appear false negative. Consistent with coeliac disease
Tissue Transglutaminase antibody (TTG IgG TAAG)	5mL venous serum	1-5 working days	Specimens should be tested within 14 days at ambient room temperature.	Index	N/A	<1.0
Protein Electrophoresis IgA/IgG/IgM	5mL venous serum	1-66working days	Specimens should be tested within 2 days of collection and stored at 20-25°C. In EMQM002 User manual under Analyte Serum Protein electrophoresis - Specimens must be tested within 10 days of collection and stored at 2-8°C or within 5 days of collection and stored at room temperature. Information to be updated.	g/L	Albumin Age 3d Age 13 Age 17 Over Globulin IgA Age 1 Age 3 Age 9 Age 13	28 - 44 38 - 54 32 - 45 34 - 50 19 - 35 0.00 - 0.83 0.20 - 1.00 0.30 - 3.00 0.50 - 3.60

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 59 of 78



Test	Specimen	Turnaround	Stability and Storage	Units	Demographics	Reference Range
	Туре	Time				
					Age 19	0.50 - 3.50
					Over >19	0.70 - 4.00
					<u>IgG</u>	
					Age 11m	2.3 - 14.1
					Age 3	4.5 - 9.2
					Age 6	5.0 - 14.6
					Age 9	5.7 - 14.7
					Over >9	7.0 - 16.0
					<u>IgM</u>	
					Age 3	0.0 - 1.50
					Age 9	0.20 - 2.10
					Age 13	0.30 - 2.4
					Age 19	0.20 - 2.6
					Over >19	0.40 - 2.30
					<u>Paraprotein</u>	- Detected/Not detected
					<u>Protein</u>	63 - 83
					Protein Immunofix	Detected/not detected

Revision: 002 Date of Issue: 18/04/2025 Page: 60 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Animal Disorders – Dog and Cat Dander(allergy) (only 3 allergy tests per sample across all allergens)	5mL venous serum	1-3 working days	Venous blood specimens should be tested within 7 days of collection and stored at 2-8°C.	kIU/l	N/A	Allergy Grading
House dust mite (allergy) (only 3 allergy tests per sample across all allergens)	5mL venous serum	1-3 working days	Venous blood specimens should be tested within 7 days of collection and stored at 2-8°C.	kIU/l	N/A	Allergy Grading
Peanut Allergy (only 3 allergy tests per sample across all allergens)	5mL venous serum	1-3 working days	Venous blood specimens should be tested within 7 days of collection and stored at 2-8°C.	kIU/l	N/A	Allergy Grading
Mixed Grass pollen (allergy) (only 3 allergy tests per sample across all allergens - Please see the list of allergens below. If you require testing for allergens not listed, please contact Enfer Medical." - Sweet Vernal Grass - Bermuda Grass - Cocksfoot	5mL venous serum	1-3 working days	Venous blood specimens should be tested within 7 days of collection and stored at 2-8°C.	kIU/I	N/A	Allergy Grading

Revision: 002 Date of Issue: 18/04/2025 Page: 61 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage	Units	Demographics	Reference Range
Anti-CCP	5mL venous serum	1-3 working days	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.	U/mL	N/A	<7 U/mL : Negative 7/10 U/mL : Equivocal >10 U/mL : Positive
Intrinsic Factor	5mL venous serum SST	1-3 working days	Venous blood specimens should be tested within 7 days of collection and stored at 2-8°C.	U/mL	N/A	0-6 u/ml
Anti-parietal cell screen	5mL venous serum SST	1-3 working days	Venous blood specimens should be tested within 2 days of collection and stored at 2-8°C.	N/A	N/A	N/A
ANCA – Vasculitis screen only	5mL venous serum SST	1-3 working days	Venous blood specimens should be tested within 7 days of collection and stored at 2-8°C.	N/A	N/A	N/A

Microbiology Analytes

Test	Specimen Type	Turnaround Time	Stability and Storage
C&S (Urine)	Female and male MSU or CSU, urine minimum volume 10ml in urine monovette ideally containing boric acid.	1-3 working days depending on +/-	Specimens should be tested within 7 days of collection and stored at 2-30°C prior to testing. Specimens collected in a non monovette device without boric acid - should be delivered to the laboratory and transferred to a monovette tube within 7 days of collection.

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 62 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage
C&S (Swab)	eSwab with regular flock swab used for collection of material from eye, ear, mouth, throat, nose, high- vaginal, superficial wound and deep wound sites MRSA Dual eSWAB White Cap used for collection of swabs from nasal and groin sites for MRSA screening Gel amies swabs used for collection of material from eye, ear, mouth, throat, nose, high-vaginal, superficial wound and deep wound swab sites. Can also be used for MRSA, VRE, CPE screens.	2-3 days depending on +/- result.	Specimens should be delivered to the laboratory within 7 days.
Faeces O,C&P (PCR preferable)	Random Faeces Separate sample should be provided for this test.	3-5 working days	Specimens should be tested within 2 days of collection and stored at 2-8°C.
Stool Investigation: Routine Bacteria/Bacterial Toxins: Salmonella, Campylobacter, Shigella, VTEC	Random Faeces	5 working days	Specimens should be tested within 2 days of collection and stored at 2-8°C.
Stool Investigation: Extended	Random Faeces	4 working days	Specimens should be tested within 2 days of collection and stored at 2-8°C.

Revision: 002 Date of Issue: 18/04/2025 Page: 63 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage
Bacteria and			
Bacterial Toxins			
C. difficile Toxin A/B			
gene, Campylobacter			
spp., Enteroaggregative			
E.coli (EAEC),			
Enteroinvasive E.coli			
(EIEC)/Shigella,			
Enterotoxigenic E.coli			
(ETEC),			
Enteropathogenic E.coli			
(EPEC), Plesiomonas			
shigelloides,			
Salmonella, Shiga-toxin			
producing E.coli (STEC)			
stx1/stx2, Shiga-toxin			
producing E.coli (STEC)			
O157:H7, Vibrio cholerae, Vibrio			
parahaemolyticus,			
Vibrio vulnificus,			
Yersinia enterocolitica			
Tersinia enterocontica			
<u>Viruses</u>			
Adenovirus 40/41,			
Astrovirus, Norovirus			
GI, Norovirus GII,			
Rotavirus A, Sapovirus			
(I, II, IV, V)			

Revision: 002 Date of Issue: 18/04/2025 Page: 64 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage
Fungal Culture	Specimens should be collected into folded paper squares secured and placed in a plastic bag or in commercially available packets designed specifically for the collection and transport of skin, nail and hair specimens.	3-8 working days	Specimens should be kept at ambient room temperature and transported and processed as soon as possible although, provided the specimens are kept dry, the fungus will remain viable for 14 days.
Stool Investigation Helicobacter Pylori Antigen	Random Faeces A separate sample should be provided for this test.	3-4 working days	Specimens should be tested within 3 days of collection and stored at 2-8°C.
Syphilis Serology Screen	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 72 hours of collection hours if stored at room temperature. Venous blood specimens should be tested within 7 days of collection if stored at 2- 8°C.
Urine Chlamydia & Gonorrhoea	Female and male urine specimens, with a final volume between the black fill lines of an Aptima urine specimen transport tube.	Next working day	Specimens should be tested within 30 days of collection and stored at 2-30°C prior to testing. Specimens collected in a non-Aptima collection device should be delivered to the laboratory and transferred to an Aptima tube within 24 hours of collection. First Catch Urine (FCU) technique should be applied in order to maximise chances of a positive specimen (due to overnight accumulation of organisms in the urethra).
STI screen (syphilis, HIV, HBsAg)	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.
Viral Hepatitis B & C screen (HBsAg + anti- HCV)	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.

Revision: 002 Date of Issue: 18/04/2025 Page: 65 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage
Hepatitis B Infection status: (HBsAg, anti-HBc)	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.
Hepatitis A IgG (HAV IgG)	5mL venous serum	1-2 working days	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.
Hepatitis B surface Antigen (HBsAg)	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.
Hepatitis B surface Antibody (Post vaccination) - AHBs	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.
Hepatitis C Antibody (anti-HCV core IgG)	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 7 days of collection and stored at 2-8°C.
Hepatitis C PCR (HCV RNA; current infection)	2 x EDTA	1-4 working days	Venous blood specimens must be tested in the laboratory within two days of sample collection.
HIV Ag/Ab Combo assay	5mL venous serum or plasma	Next working day	Venous blood specimens should be tested within 14 days of collection and stored at 2-8°C.
Herpes Simplex Virus PCR	Aptima multisite swab/Urine	5-6 working days	Venous blood specimens should be tested within 2 days of collection and stored at 2-8°C.
Varicella Zoster Virus (VZV) IgG (Immune status)	5mL venous serum	1-3 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.
Measles/Mumps/Rubella IgG screen	5mL venous serum	1-3 working days	Specimens should be tested within 7 days of collection and stored at 2-8°C.

Revision: 002 Date of Issue: 18/04/2025 Page: 66 of 78



Test	Specimen Type	Turnaround Time	Stability and Storage
Mycobacterial Investigation TB/ TB Culture	Sputum in 60ml Sterile Container	Up to 8 weeks	Specimens should be tested within 3 days of collection and stored at 2-8°C. Stable 72 hours max, best kept refrigerated. Transport ambient urgently.
Individual serology screens (HIV, Hep B, Hep C, Hep A)	See individual test information above.	See individual test information above.	See individual test information above.
Individual Molecular screens (HSV PCR)	Aptima multisite swab/urine	2-5 working days.	Specimens should be tested within 7 days of collection and stored at 2-8°C.

APPENDIX 2.1: Sickle Cell Screen/Thalassaemia Demographics and Reference Range

TFC	TFC Description	Range	Units
ARHB	Haemoglobin F	0-1	%
HA2	Haemoglobin A2	1.5-3.5	%
HBC	Haemoglobin C	N/A	%
НВСО	Conclusion:	N/A	
HBDB	Haemoglobin D	N/A	
HBEC	Haemoglobin phenotype	N/A	

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 67 of 78



HBGL	HAEMOGLOBIN (g/L)	Age - 2d - 135-195 4d - 145 - 225 8d - 135-215 21d - 125-205 1m - 100-180 2m - 90-140 2 - 100 - 135 3 - 105 - 135 7 - 115 - 145 13 - 115 - 155 Gender - f - 115 - 155 m - 130 - 170 u - 115 - 170	g/L	
HBS	Haemoglobin S	N/A	%	
HBX	Haemoglobin E	N/A	%	

Revision: 002 Date of Issue: 18/04/2025 Page: 68 of 78



НСТ	НСТ	Age - 1d - 0.42 - 0.6 4d - 0.45 - 0.67 8d - 0.42 - 0.66 21d - 0.39 - 0.63 1m - 0.31 - 0.55 2m - 0.28 - 0.42 3m - 0.29 - 0.41 3 - 0.33 - 0.39 13 - 0.35 - 0.45 Gender - f - 0.33 - 0.45 m - 0.37 - 0.5 u - 0.33 - 0.5		
HGSC	Haemoglobin S plus C	N/A	%	
HGSD	Haemoglobin S plus D	N/A	%	
HPLC	Haemoglobin A0	N/A	%	
MCH	MCH	Age - 4d - 31 - 37 1m - 28-40 2m - 26-34 3m - 25-35 3 - 23-31 13 - 25-33 Unk - 27-33.5	pg	

Revision: 002 Date of Issue: 18/04/2025 Page: 69 of 78



MCV	MCV	Age - 2d - 97-118 4d - 95-121 8d - 88-126 21d - 86-124 1m - 85-123 2m - 77-115 3m - 74-118 3 - 70-86 7 - 75-87 13 - 77-94 Unk - 80-99	fL
RBC	RED CELL COUNT	Age - 2d - 3.9-5.3 4d - 4-6.6 8d - 3.9 - 6.3 21d - 3.6-6.2 1m - 3-5.4 2m - 2.7-4.9 3m - 3.1 - 4.5 3 - 3.7 - 5.3 7 - 3.9-5.3 13 - 4-5.2 Gender - f - 3.95 - 5.15 m - 4.4-5.8 u - 3.95 - 5.8	x10^12/L

Revision: 002 Date of Issue: 18/04/2025 Page: 70 of 78



APPENDIX 3: Specimen receipt anomalies (Specimen receipt anomaly protocol and codes)

Reason for SRA	SRA Code	Comment
Unlabelled Specimen* (Will NOT be tested)	SRA_NL	We have received a request form for the above patient. However, the accompanying specimen was not labelled. Testing will NOT proceed. Please send a repeat specimen if clinically indicated.
Insufficient identifiers* (Will NOT be tested)	SRA_OP1	Please note that the specimen received was not labelled with the minimum requirement of three patient identifiers. Testing will NOT proceed. To prevent patient identification errors please ensure all request forms are completed with a minimum of 3 patient identifiers which match the specimen.
Form not Complete* (Will NOT be tested)	SRA_FNC	Please note, the request form received for this patient was not fully completed. Testing will NOT proceed. To prevent patient identification errors please ensure all request forms are completed with a minimum of 3 patient identifiers which match the specimen.

Document No: EMQM007 Issued by: M. Buggy Approved by: P. Simmons Revision: 002 Date of Issue: 18/04/2025 Page: 71 of 78



Reason for SRA	SRA Code	Comment
Discrepant DOB* (Will be tested, hold until patient details are confirmed)	SRA_DDB	Please confirm patient Date of Birth. DOB on specimen: DOB on request form:
Discrepant Name* (Will be tested, hold until patient details are confirmed)	SRA_DPN	Please confirm patient name Name on specimen: Name on request form:
Gender unknown (Will be tested, hold until patient details are confirmed)	SRA_GEN	Please confirm patient gender.
No specimen received* (Will NOT be tested)	SRA_NSR	A form was received for the above patient. However, there was no accompanying specimen. Testing will NOT proceed.
Unlabelled Specimen* (Will NOT be tested)	SRA_NL	We have received a request form for the above patient. However, the accompanying specimen was not labelled. Testing will NOT proceed. Please send a repeat specimen if clinically indicated.

Revision: 002 Date of Issue: 18/04/2025 Page: 72 of 78



Reason for SRA	SRA Code	Comment
Insufficient identifiers* (Will NOT be tested)	SRA_OP1	Please note that the specimen received was not labelled with the minimum requirement of three patient identifiers. Testing will NOT proceed. To prevent patient identification errors please ensure all request forms are completed with a minimum of 3 patient identifiers which match the specimen.
Form not Complete* (Will NOT be tested)	SRA_FNC	Please note, the request form received for this patient was not fully completed. Testing will NOT proceed. To prevent patient identification errors please ensure all request forms are completed with a minimum of 3 patient identifiers which match the specimen.
Discrepant DOB* (Will be tested, hold until patient details are confirmed)	SRA_DDB	Please confirm patient Date of Birth. DOB on specimen: DOB on request form:
Discrepant Name* (Will be tested, hold until patient details are confirmed)	SRA_DPN	Please confirm patient name Name on specimen: Name on request form:
Gender unknown (Will be tested, hold until patient details are confirmed)	SRA_GEN	Please confirm patient gender.

Revision: 002 Date of Issue: 18/04/2025 Page: 73 of 78



Reason for SRA	SRA Code	Comment
No specimen received* (Will NOT be tested)	SRA_NSR	A form was received for the above patient. However, there was no accompanying specimen. Testing will NOT proceed.
Compromised specimen. (Will be tested, confirm with client and consultant)	SRA_ Com_Tested	This specimen has been compromised. Please interpret the results with caution.
No Form Received* (Will NOT be tested)	SRA_SNF	Please note, no request form was received with the specimen for this patient. Please send a repeat specimen and request form for testing if clinically relevant. Testing will NOT proceed.
Specimen Leaked* (Will NOT be tested)	SRA_LK	The specimen received for the above patient has LEAKED IN TRANSIT. This specimen will NOT be tested. Please send a repeat specimen if clinically indicated.
Specimen Date* (Will NOT be tested)	SRA_SDT	The collection date on the specimen received exceeds the time period for testing. This specimen will NOT be tested. Please send a repeat specimen if clinically indicated.
Specimen Stability (Will NOT be tested)	SRA_STAB	The specimen received for the above patient was beyond its stability. Please send a repeat specimen if clinically indicated.

Revision: 002 Date of Issue: 18/04/2025 Page: 74 of 78



Reason for SRA	SRA Code	Comment	
Incorrect collection device used. (Will NOT be tested)	SRA_SC	The specimen received for this patient was collected in the incorrect collection device. This specimen will NOT be tested. Please send a repeat specimen if clinically indicated.	
Matching request form/specimen received* (Will NOT be tested)	SRA_SCF	This specimen was received with a matching request form, however a second specimen for a different patient was also within the package. As we are unable to confirm the provenance of the specimen, testing will NOT proceed. Please send a repeat specimen if clinically indicated.	
Matching request form/specimen received* (Will NOT be tested)	SRA_SIF	The specimen received for the above patient was received with a matching request form however a second form for a different patient was also received. As we are unable to confirm the provenance of this specimen, testing will NOT proceed. Please send a repeat specimen if clinically indicated.	
Insufficient specimen (Will NOT be tested)	SRA_INS	Insufficient specimen for testing. Testing will NOT proceed.	
Expired Collection Device* (Will NOT be tested)	SRA_EXP _/_/_	The specimen received for the above patient was collected in an expired device. This specimen will NOT be tested. Please send a repeat specimen if clinically indicated.	
Duplicated Specimen* (Will NOT be tested)	SRA_DUP	Duplicate specimens and PRF forms were received for this patient, the PRFs were dated with differing request times. We are unable to process these	

Revision: 002 Date of Issue: 18/04/2025 Page: 75 of 78



Reason for SRA	SRA Code	Comment
		specimens as the origin of the specimen cannot be confirmed. Please send a repeat specimen if clinically indicated.
Process Error (Will NOT be tested)	SRA_PE	We apologise that this specimen could NOT be tested due to a laboratory processing error. Please send a repeat specimen if clinically indicated.
Specimen Mismatch (Specimen received with form for another patient)* (Will NOT be tested)	SRA_MMAT	The specimen for the above-named patient was received with a request form for a different patient. Testing will NOT proceed. Please send a repeat specimen if clinically indicated.
Specimen Leaked* (Will be tested)	SRA_MESS	The outside of the tube containing this specimen was contaminated, posing a *** POTENTIAL RISK OF INFECTION*** Testing will proceed. Please ensure that this does not occur in the future.
Damaged Label (Will NOT be tested)	SRA_DAML	The specimen(s) received for this patient had a damaged label on the collection device and the patient information cannot be confirmed. Testing will NOT proceed. Please send a repeat specimen if clinically indicated.
Damaged collection device (Will NOT be tested)	SRA_DAMCD	The specimen for this patient was received in a damaged collection device. Testing will NOT proceed. Please send a repeat specimen if clinically indicated.
Empty collection device (Will NOT be tested) SRA_I		A request form was received for the above patient however, the accompanying collection device was empty. Testing will NOT proceed. Please send a repeat specimen if clinically indicated.

Revision: 002 Date of Issue: 18/04/2025 Page: 76 of 78



Reason for SRA	SRA Code	Comment
Undetermined content (Will NOT be tested)	SRA_UDC	We received a specimen for this patient however, the laboratory could not determine the contents of the specimen. Testing will NOT proceed. Please send a repeat specimen if clinically indicated.
Discrepant Date Format Will be tested, hold until date details are confirmed	SRA_DDF	Please note the collection date on the specimen received is in a discrepant format.
Collection Time (Will be tested. Hold, confirm time if clinically relevant)	SRA_Time	Please note there is no collection time for the specimen received.
Collection Date & Time (Will be tested. Hold, confirm date & time if clinically relevant)	SRA_DANDT	Please note there is no collection date and time for the specimen received.
Incorrectly used device Will NOT be tested	SRA_IUD	Please note the specimen received was incorrectly collected and not suitable for analysis. Testing will not proceed. Please send a repeat specimen if clinically indicated.
Haemolysed specimen (Will NOT be tested)	SRA_HAEM	Please note this specimen was grossly haemolysed and is not suitable for analysis. Testing will NOT proceed.
Paediatric specimen (Will NOT be tested)	SRA_PAED	Please note the specimen received was for a paediatric patient. Testing will NOT proceed.

Revision: 002 Date of Issue: 18/04/2025 Page: 77 of 78



Reason for SRA	SRA Code	Comment
Pregnancy Status (Will be tested)	SRA_PNN	A form was received for the above patient. However please confirm patient pregnancy status.
Invalid Test Request (Will NOT be tested)	SRA_NOTEST	Please note you have requested a test currently not available on the HSE approved test List. Please contact Enfer Medical on 045 819000 for further details.
Repeat sample (Will be tested)	SRA_Repeat	Repeat sample, already confirmed. Not to be sent for confirmation at client's request.
Sample Clotted (Will NOT be tested)	SRA_CLOT	This sample was clotted and is unsuitable for analysis. Please send a repeat sample if clinically indicated.
Test request withdrawn by client (Will NOT be tested)	SRA_TestWD	Testing not performed as per client request.
Illegible writing (Will NOT be tested)	SRA_Illegible	Please note the patient request form for the sample received was illegible. Testing will NOT proceed.
Specimen Stability (Will be tested)	SRA_STAB_TESTED	This sample was tested despite arriving to the laboratory outside the recommended timeframe from the date of collection. Please interpret the results in light of this limitation and advise repeat sample if clinically indicated.

Revision: 002 Date of Issue: 18/04/2025 Page: 78 of 78